<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67085</article-id><article-id pub-id-type="doi">10.7554/eLife.67085</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-224486"><name><surname>Unterman</surname><given-names>Irene</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5697-9612</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-226377"><name><surname>Bloch</surname><given-names>Idit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-226379"><name><surname>Cazacu</surname><given-names>Simona</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6085-4177</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-226397"><name><surname>Kazimirsky</surname><given-names>Gila</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-88771"><name><surname>Ben-Zeev</surname><given-names>Bruria</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-226381"><name><surname>Berman</surname><given-names>Benjamin P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2099-9005</contrib-id><email>ben.berman@mail.huji.ac.il</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-226382"><name><surname>Brodie</surname><given-names>Chaya</given-names></name><email>chaya@brodienet.com</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-174447"><name><surname>Tabach</surname><given-names>Yuval</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9521-3217</contrib-id><email>yuvaltab@ekmd.huji.ac.il</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada</institution><addr-line><named-content content-type="city">Jerusalem</named-content></addr-line><country>Israel</country></aff><aff id="aff2"><label>2</label><institution>Hermelin Brain Tumor Center, Henry Ford Hospital</institution><addr-line><named-content content-type="city">Detroit</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University</institution><addr-line><named-content content-type="city">Ramat-Gan</named-content></addr-line><country>Israel</country></aff><aff id="aff4"><label>4</label><institution>Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center</institution><addr-line><named-content content-type="city">Ramat Gan</named-content></addr-line><country>Israel</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Perry</surname><given-names>George H</given-names></name><role>Reviewing Editor</role><aff><institution>Pennsylvania State University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Perry</surname><given-names>George H</given-names></name><role>Senior Editor</role><aff><institution>Pennsylvania State University</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>06</day><month>08</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67085</elocation-id><history><date date-type="received" iso-8601-date="2021-02-01"><day>01</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-07-23"><day>23</day><month>07</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-02-15"><day>15</day><month>02</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.02.14.431162"/></event></pub-history><permissions><copyright-statement>© 2021, Unterman et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Unterman et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67085-v1.pdf"/><abstract><p>Inactivating mutations in the Methyl-CpG Binding Protein 2 (MECP2) gene are the main cause of Rett syndrome (RTT). Despite extensive research into MECP2 function, no treatments for RTT are currently available. Here, we used an evolutionary genomics approach to construct an unbiased MECP2 gene network, using 1028 eukaryotic genomes to prioritize proteins with strong co-evolutionary signatures with MECP2. Focusing on proteins targeted by FDA-approved drugs led to three promising targets, two of which were previously linked to MECP2 function (IRAK, KEAP1) and one that was not (EPOR). The drugs targeting these three proteins (Pacritinib, DMF, and EPO) were able to rescue different phenotypes of MECP2 inactivation in cultured human neural cell types, and appeared to converge on Nuclear Factor Kappa B (NF-κB) signaling in inflammation. This study highlights the potential of comparative genomics to accelerate drug discovery, and yields potential new avenues for the treatment of RTT.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>rett syndrome</kwd><kwd>phylogenetic profiling</kwd><kwd>comparative genomics</kwd><kwd>pacritinib</kwd><kwd>erythropoietin</kwd><kwd>dimethyl fumarate</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id><institution>Israel Science Foundation</institution></institution-wrap></funding-source><award-id>1591/19</award-id><principal-award-recipient><name><surname>Tabach</surname><given-names>Yuval</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009006</institution-id><institution>Integra LifeSciences</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Tabach</surname><given-names>Yuval</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Beethoven Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Berman</surname><given-names>Benjamin P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel comparative genomics framework identifies MECP2 network proteins targeted by existing drugs, with three drugs validated in an in vitro Rett syndrome model.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Rett syndrome (RTT [MIM: #312750]) is a rare genetic disorder caused by mutations in the methyl-CpG binding protein 2 (<italic>MECP2</italic>) gene (<xref ref-type="bibr" rid="bib1">Amir et al., 1999</xref>). It is an X-linked dominant disorder, almost exclusively affecting females. RTT is characterized by normal early development followed by regression, loss of purposeful hand movements, and intellectual disability (<xref ref-type="bibr" rid="bib56">Liyanage and Rastegar, 2014</xref>). Characteristics of the disease such as age of onset, range of symptoms, and their severity vary between patients (<xref ref-type="bibr" rid="bib69">Neul et al., 2008</xref>). The MECP2 protein has a role in transcriptional regulation but its exact mechanism of action, co-factors and downstream targets, are not fully characterized (<xref ref-type="bibr" rid="bib78">Picard and Fagiolini, 2019</xref>).</p><p>The MECP2 protein, as a transcriptional regulator, has been linked to both gene silencing and activation (<xref ref-type="bibr" rid="bib38">Horvath and Monteggia, 2018</xref>). It binds methylated CG dinucleotides through its methyl-binding domain and has a transcriptional repression domain that mediates binding to co-repressor proteins (<xref ref-type="bibr" rid="bib59">Lyst et al., 2013</xref>). These two domains are hotspots for missense, nonsense, and frameshift mutations for RTT disease (<xref ref-type="bibr" rid="bib81">Ragione et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Krishnaraj et al., 2017</xref>). Transcriptomic analyses of RTT patient postmortem brain tissues, blood samples, cell lines, and murine models (<xref ref-type="bibr" rid="bib88">Shovlin and Tropea, 2018</xref>) have revealed hundreds of affected genes but with a low degree of overlap between studies (<xref ref-type="bibr" rid="bib78">Picard and Fagiolini, 2019</xref>).</p><p>Therapies aiming to restore <italic>MECP2</italic> loss of function are in early development stages and are not approved for patients. These include attempts at read-through inducing drugs to overcome nonsense mutations (<xref ref-type="bibr" rid="bib12">Brendel et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Merritt et al., 2020</xref>), X reactivating therapies to allow expression of silenced endogenous <italic>MECP2 (12)</italic>, and gene therapy treatments to introduce wild-type <italic>MECP2</italic> copies into the brain (<xref ref-type="bibr" rid="bib35">Guy et al., 2007</xref>; <xref ref-type="bibr" rid="bib32">Garg et al., 2013</xref>). Furthermore, current gene therapy methods show limited transduction efficiency and are unable to modify all cells in the target tissue (<xref ref-type="bibr" rid="bib30">Gadalla et al., 2013</xref>). Targeting factors downstream of MECP2 offers a promising avenue which could allow for partial amelioration of Rett symptoms, without the severe neurological phenotypes associates with MECP2 overexpression (<xref ref-type="bibr" rid="bib17">Chao and Zoghbi, 2012</xref>; <xref ref-type="bibr" rid="bib82">Ramocki et al., 2009</xref>).</p><p>One major downstream target of MECP2 is brain-derived neurotrophic factor (BDNF) (<xref ref-type="bibr" rid="bib18">Chen et al., 2003</xref>), a key modulator of neuronal development and function. BDNF levels are reduced in symptomatic MECP2 KO mice (<xref ref-type="bibr" rid="bib53">Kline et al., 2010</xref>) and experimental interventions that increase BDNF levels improve RTT-like phenotypes (<xref ref-type="bibr" rid="bib16">Chang et al., 2006</xref>). The IGF-1 protein potentiates BDNF activity, and treatments with recombinant human IGF-1 and its analogs have led to improvement in several clinical measurements (<xref ref-type="bibr" rid="bib50">Khwaja et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Glaze et al., 2019</xref>), with a trial of an IGF-1 synthetic analog currently in Phase 3 (NCT04181723). Additional trials include the administration of triheptanoin supplementation which is being investigated in a Phase two clinical trial (NCT02696044) to target mitochondrial dysfunction in RTT (<xref ref-type="bibr" rid="bib75">Park et al., 2014</xref>). Other interventions, such as ketamine (NCT03633058), targeting N-methyl-D-aspartate receptor (NMDAR) dysfunction, and Anavex 2–73 (NCT03758924), aimed at restoring mitochondrial dysfunction (<xref ref-type="bibr" rid="bib49">Kaufmann et al., 2019</xref>), are currently being studied. Histone deacetylases (HDACs) mediate MECP2 gene repression, and have also been suggested as therapeutic targets for Rett syndrome (<xref ref-type="bibr" rid="bib89">Shukla and Tekwani, 2020</xref>), which may act on BDNF trafficking (<xref ref-type="bibr" rid="bib103">Xu et al., 2014</xref>). The lack of a successful therapy to date emphasizes the need for accurate and comprehensive mapping of the MECP2 network with a focus on targetable proteins that could be used for interventions (<xref ref-type="bibr" rid="bib100">Vashi and Justice, 2019</xref>). Here, we use a genomics approach that has thus far not been applied to MECP2 (phylogenetic profiling), combined with data from drug target databases, to construct such a map.</p><p>A well-tested approach for gene functional prediction and identification of functional gene networks is phylogenetic profiling (PP), which analyzes gene conservation patterns across an evolutionary related set of organisms (<xref ref-type="bibr" rid="bib77">Pellegrini et al., 1999</xref>). Genes with similar evolutionary patterns are functionally coupled, irrespective of sequence homology (<xref ref-type="bibr" rid="bib23">Date and Marcotte, 2003</xref>). PP was used successfully to predict protein function (<xref ref-type="bibr" rid="bib27">Enault et al., 2004</xref>; <xref ref-type="bibr" rid="bib26">Eisen and Wu, 2002</xref>; <xref ref-type="bibr" rid="bib42">Jiang, 2008</xref>; <xref ref-type="bibr" rid="bib62">Merchant et al., 2007</xref>), protein interactions (<xref ref-type="bibr" rid="bib51">Kim and Subramaniam, 2006</xref>; <xref ref-type="bibr" rid="bib91">Sun et al., 2005</xref>) and protein localization within the cell (<xref ref-type="bibr" rid="bib61">Marcotte et al., 2000</xref>; <xref ref-type="bibr" rid="bib74">Pagliarini et al., 2008</xref>; <xref ref-type="bibr" rid="bib4">Avidor-Reiss et al., 2004</xref>; <xref ref-type="bibr" rid="bib37">Hodges et al., 2012</xref>). When a pathway becomes non-functional in a specific lineage (often due to loss of a key gene in the pathway), then other genes involved in the pathway may lose the fitness advantage they provide to the organism if they are not involved in other important pathways/functions. PP captures these pathway-level loss events, providing a quantitative measurement of functional relatedness and prioritizing those genes minimally involved in the same pathway over pleiotropic genes required in multiple pathways. This property is especially attractive for drug development, where the goal to is target the most specific proteins possible. Because PP is based on evolutionary dynamics rather than protein expression or sequence/structure features, it produces results that are highly complementary to traditional methods (<xref ref-type="bibr" rid="bib24">Dey et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Arkadir et al., 2019</xref>).</p><p>In our recent work, we developed an improved version of PP that normalizes signals across hundreds of eukaryotic genomes to identify important new members of cellular and disease pathways (<xref ref-type="bibr" rid="bib3">Arkadir et al., 2019</xref>; <xref ref-type="bibr" rid="bib87">Sherill-Rofe et al., 2019</xref>; <xref ref-type="bibr" rid="bib93">Tabach et al., 2013a</xref>; <xref ref-type="bibr" rid="bib94">Tabach et al., 2013b</xref>; <xref ref-type="bibr" rid="bib86">Schwartz et al., 2013</xref>). As protein function and evolution are very complex (<xref ref-type="bibr" rid="bib10">Bloch et al., 2020</xref>), co-evolution within a local lineage (i.e. mammals, vertebrates, fungi, etc.) can provide complementary evidence, and is especially informative for genes with multiple functions that show complex or recent evolution (<xref ref-type="bibr" rid="bib87">Sherill-Rofe et al., 2019</xref>). We recently incorporated a clade-specific analysis into our Normalized Phylogenetic Profile (NPP) software pipeline (<xref ref-type="bibr" rid="bib97">Tsaban et al., 2021</xref>), which is used for all the analyses in this study. We have used several functional databases including CORUM (<xref ref-type="bibr" rid="bib85">Ruepp et al., 2008</xref>), KEGG (<xref ref-type="bibr" rid="bib47">Kanehisa and Goto, 2000</xref>), and REACTOME (<xref ref-type="bibr" rid="bib40">Jassal et al., 2020</xref>) to validate the NPP method and show that it recovers known protein complexes and pathways with higher specificity and sensitivity than other phylogenetic methods (<xref ref-type="bibr" rid="bib10">Bloch et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Tsaban et al., 2021</xref>).</p><p>We combined our PP-derived interaction map of MECP2 with drug targeting databases to select new candidate drugs for RTT. There are thousands of known bioactive compounds collected in databases such as Drug-Gene interaction database (DGIdb) (<xref ref-type="bibr" rid="bib22">Cotto et al., 2018</xref>) and Open Targets (<xref ref-type="bibr" rid="bib73">Oxford Academic, 2019</xref>), that contain information about validated direct or indirect effect on specific proteins or pathways. Network-based drug discovery methods are emerging as important tools to identify novel drug targets and predict the drug’s mode of action and potential side-effects (<xref ref-type="bibr" rid="bib39">Iorio et al., 2013</xref>), and have been associated with higher success rates in clinical trials (<xref ref-type="bibr" rid="bib68">Nelson et al., 2015</xref>; <xref ref-type="bibr" rid="bib80">Pushpakom et al., 2019</xref>). From our PP network, we selected three proteins that showed robust co-evolution with MECP2 across multiple evolutionary scales, had related roles in inflammation, and could be targeted by pharmacologically-validated compounds. These three compounds – pacritinib, EPO and DMF – were then functionally validated in <italic>MECP2</italic> Knock-Down (KD) human neural cells, including microglia, astrocytes and neural stem cells. The ability of all these drugs to reverse some aspects of the MECP2-KD phenotypes demonstrates how comparative genome analysis can be used to understand and target this disease network.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Phylogenetic profile analysis of MECP2 in eukaryotes and mammals identifies MECP2 co-evolved genes</title><p>To trace the evolutionary history of <italic>MECP2</italic>, we used BLASTP (<xref ref-type="bibr" rid="bib14">Camacho et al., 2009</xref>) to compare the MECP2 protein to the proteomes of 1028 eukaryotic species. We repeated the process for each of 20,192 human transcripts to generate a profile of conservation for each human gene. The scores were normalized according to sequence length and the evolutionary distance between humans and the queried species as described previously (<xref ref-type="bibr" rid="bib94">Tabach et al., 2013b</xref>; <xref ref-type="bibr" rid="bib10">Bloch et al., 2020</xref>). This Normalized Phylogenetic Profile (NPP) describes how conserved a transcript is in each species across the tree of life, compared to its expected conservation. Genes with similar NPPs (i.e. genes that are either conserved or lost as a group) are functionally related, often belonging to the same pathway (<xref ref-type="bibr" rid="bib87">Sherill-Rofe et al., 2019</xref>; <xref ref-type="bibr" rid="bib93">Tabach et al., 2013a</xref>; <xref ref-type="bibr" rid="bib94">Tabach et al., 2013b</xref>; <xref ref-type="bibr" rid="bib86">Schwartz et al., 2013</xref>). We have shown that both across-clade and within-clade measures of co-evolution can be informative, and thus we computed NPPs both across all eukaryotes (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) and within mammals (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>) as described previously (<xref ref-type="bibr" rid="bib87">Sherill-Rofe et al., 2019</xref>; <xref ref-type="bibr" rid="bib10">Bloch et al., 2020</xref>; <xref ref-type="bibr" rid="bib97">Tsaban et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Braun et al., 2020</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The phylogenetic profile of MECP2.</title><p>(<bold>A</bold>) The Normalized Phylogenetic Profile (NPP) of <italic>MECP2</italic> in eukaryotes along with the top 5000 co-evolved proteins. Each row represents one human protein, ordered by Pearson correlation to <italic>MECP2,</italic> with the top 200 proteins labeled as E200. Darker color indicates higher normalized conservation of the protein in each species. Organisms are grouped by phylogenetic clade, and clustered within each clade. (<bold>B</bold>) The NPP of <italic>MECP2</italic> in 51 mammals along with the 5000 top co-evolved proteins, ordered by Pearson correlation to MECP within mammals. The top 200 proteins are labeled as M200. (<bold>C</bold>) Gene overlap of the top 200 most co-evolved genes in eukaryotes and mammals, listing the 10 gene names listed in both.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Scaled phylogenetic profiles of all human genes by similarity to MECP2.</title><p>(<bold>A</bold>) NPP profiles of human genes in 1028 eukaryote species, ordered by the Pearson correlation to the profile of MECP2. (<bold>B</bold>) Phylogenetic profiles of human genes in 51 mammals, scaled to highlight the conservation patterns within the clade. (<bold>C</bold>) GeneAnalytics enrichment for the 390 union set of E200 and M200. Within each organ, individual anatomical compartment scores are displayed in dots. (<bold>D</bold>) Overlap between the 390 union set of E200 and M200 with all STRING MECP2 coexpression, experimental and textmining categories. (<bold>E</bold>) Overlap between the 200 genes most correlated to MECP2 in mammals (M200) and eukaryotes (E200) with the 390 genes most correlated to MECP2 through STRING.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig1-figsupp1-v1.tif"/></fig></fig-group><p>We first used NPP scores to sort all human genes by their phylogenetic similarity to MECP2 across eukaryotes (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We selected the top 200 genes (the ‘E200’ set), which showed high correlation (R&gt;0.47) with <italic>MECP2</italic>. Similarly, we used NPP scores within the mammalian clade (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>) to select the top 200 mammal-centric genes (the ‘M200’ set), which also showed high <italic>MECP2</italic> correlations (R&gt;0.49) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) [code is available on <ext-link ext-link-type="uri" xlink:href="https://github.com/GuIrene/MECP2_phylogeny">GitHub</ext-link> (<xref ref-type="bibr" rid="bib99">Unterman et al., 2021</xref>; copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:e2c60f2c5038244f7192b1070c80c10bad4daeb0;origin=https://github.com/GuIrene/MECP2_phylogeny;visit=swh:1:snp:0c28d2131db499777078eb129237064f9b0c9be0;anchor=swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad">swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad</ext-link>)]. These two lists find correlated evolution at different scales, billions of years for eukaryotes and hundreds of millions for mammals. Therefore, the M200 set may show genes more recently co-evolved with MECP2. E200 and M200 had very different functional properties, based on STRING enrichment to Gene Ontology and other annotation sets (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) The E200 list was enriched in a number of different functional categories, with some of the most significant related to innate immunity and the immune response. These included MHC Class II receptor activity and peptidoglycan receptor activity in GO, and the associated autoimmunity Asthma, Allograft rejection, and Type I in KEGG. In contrast, the M200 list had almost no functional enrichment, except for the general ‘Disease’ category within Uniprot annotated keywords.</p><p>The E200 and M200 lists had 10 genes in common (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). As mammals are included within the eukaryote analysis, the two lists are not independent and thus the expected degree of overlap is hard to determine. Nevertheless, in two independent gene lists of this size we would only expect two overlapping genes. We thus considered the set of 10 overlapping genes, as well as the full union set of 390 genes, as two tiers of candidates for further exploration. A GeneAnalytics query of the 390 gene union set revealed it was enriched with genes expressed in the brain (p-value &lt; 0.00024), with 79 genes linked to the cerebral cortex and 54 to the cerebellum (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib6">Ben-Ari Fuchs et al., 2016</xref>). Only 24 of the 390 gene list were overlapping with a length-matched list of MECP2 interactions from STRING (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D,E</xref>), highlighting the complementary role phylogenetic analysis to other measurements and predictions of protein interaction.</p></sec><sec id="s2-2"><title>MECP2 druggable protein network identifies several drug targets located in evolutionarily conserved chromosomal clusters</title><p>We chose to focus on the subset of <italic>MECP2</italic> co-evolved genes that could be targeted by readily available compounds. This approach allows for straightforward functional testing in both in vitro and animal models of <italic>MECP2</italic> inactivation and moves us closer to the ultimate goal of identifying a candidate therapeutic for RTT. Using DGIdb (<xref ref-type="bibr" rid="bib22">Cotto et al., 2018</xref>) and Open Targets (<xref ref-type="bibr" rid="bib73">Oxford Academic, 2019</xref>), we searched specific drug-gene interaction types (e.g. inhibitory, activating) to identify direct effects on the 390 candidate genes. Open Targets identified such protein-compound interactions for 11 proteins from our list, and DGIdb identified an additional 22, resulting in 33 druggable proteins in the MECP2 phylogenetic network. MECP2-linked proteins were neither more or less druggable than other proteins in the genome, since the number expected by chance was 39.9±6.0.</p><p>Two of the 33 druggable NPP-linked proteins (IRAK1 and EPOR) were found in both the eukaryotic E200 and the mammalian M200 lists, and were targeted by compounds with clinical efficacy and acceptable safety profiles (Pacritinib and EPI), making these immediately attractive for further study. In a STRING (<xref ref-type="bibr" rid="bib92">Szklarczyk et al., 2019</xref>) functional interaction map, which is based on independent data types, IRAK1 was one of the six proteins functionally linked to MECP2, whereas EPOR had no known functional links (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). To identify additional targets among the 31 druggable NPP-linked proteins found in only one of the E200 and M200 lists, we investigated chromosomal clusters of genes with MECP2-linked genes, since clustered genes often indicate a shared evolutionary function. Indeed, IRAK1 is directly adjacent to MECP2 on an evolutionary conserved chromosomal band on the X chromosome (<xref ref-type="fig" rid="fig2">Figure 2B</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In a chromosomal clustering analysis of all MECP2-linked genes, the chr19p13.2 band contained more MECP2 co-evolved genes than any other in the genome (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Unexpectedly, this 5.6 Mb domain contained 5 of the 33 druggable MECP2 coevolved genes - EPOR, DNMT1, ICAM1, ICAM3, and KEAP1 (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), making this the most strongly enriched band in the genome (p&lt;1E-5, <xref ref-type="fig" rid="fig2">Figure 2D</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Topologically Associated Domains (TADs) define the 3D organization of functionally co-regulated gene clusters (<xref ref-type="bibr" rid="bib29">Fritz et al., 2019</xref>), and the entire chr19p13.2 gene cluster defines a single TAD-based high-resolution Hi-C mapping (<xref ref-type="bibr" rid="bib83">Rao et al., 2014</xref>; <xref ref-type="fig" rid="fig2">Figure 2E</xref>). Additionally, this region has been shown to be bound by MECP2 (<xref ref-type="bibr" rid="bib105">Yasui et al., 2007</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The <italic>MECP2</italic> druggable genes network.</title><p>(<bold>A</bold>) The 390 genes co-evolved with <italic>MECP2</italic> in either eukaryotes or mammals contain 33 genes that are targets of known drugs/compounds. These genes are shown in a STRING interaction graph, with known gene-gene interactions shown as colored edges, and those with very strong co-evolution (Pearson correlation &gt; 0.7) shown as gray edges. The two proteins co-evolved in both eukaryotes and mammals (EPOR and IRAK1) are colored yellow and the four other genes found at chr19p13.2 are colored purple. (<bold>B</bold>) Genomic location of MECP2 interacting genes along chromosome X in humans and mice. (<bold>C</bold>) Karyotype band locations of MECP2 and the 390 co-evolved genes. * p&lt;0.05, **p&lt;0.01, *** p&lt;0.001 (<bold>D</bold>) Genomic location of MECP2 interacting genes along chr19p13.2 in humans and chromosome nine in mice. (<bold>E</bold>) Intra-chromosomal Hi-C contact heatmap for the chr19p13.2 locus in GM12878 cells, adapted from the 3D Genome Browser (<xref ref-type="bibr" rid="bib101">Wang et al., 2018</xref>). Genes in the MECP2 network are shown, with other genes hidden for clarity. TADs called by 3D Genome Browser shown in blue/yellow track, with a super-TAD containing MECP2 genes outlined in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Synteny in the Chr19p13.2 locus.</title><p>(<bold>A</bold>) NCBI Genome Data Viewer view of the genomic locations of DNMT1, ICAM1, ICAM3, KEAP1, and EPOR (top panel, genes highlighted). The gene orthologs are shown in <italic>Mus musculus</italic> chromosome 9 (bottom panel). (<bold>B</bold>) Inference of the synteny in ancestral species from Genomicus. Each row represents the same genomic locus at an ancestral state. Each gene is represented by a different color, and selected genes are annotated below. EPOR, ICAM1, ICAM3, KEAP1, and DNMT1 maintain their relative positions as far as the mammalian ancestral genome.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Synteny between MECP2 and IRAK1.</title><p>(<bold>A</bold>) NCBI Genome Data Viewer view of the genomic locations of MECP2 and IRAK1 (top panel). The gene orthologs are shown in <italic>Mus musculus</italic> chromosome X (bottom panel). (<bold>B</bold>) Inference of the synteny in ancestral species from Genomicus.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig2-figsupp2-v1.tif"/></fig></fig-group><p>For the two druggable proteins found in both NPP lists (IRAK1, EPO1) and the other four proteins located in the chr19p13.2 TAD (DNMT1, ICAM1, ICAM3, KEAP1), we further investigated the associated drug’s mode of action and efficacy and safety profile in other contexts. IRAK1 has been identified as a key intermediary in NF-κB signaling in RTT, with MECP2 directly binding the IRAK1 promoter to regulate its expression in MECP2-null mouse brains and <italic>NFΚB1</italic> dramatically increasing lifespan in <italic>MECP2</italic> null mice (<xref ref-type="bibr" rid="bib52">Kishi et al., 2016</xref>). Pacritinib is a JAK2/FLT3 inhibitor with IRAK1 inhibiting capabilities (<xref ref-type="bibr" rid="bib41">Jensen et al., 2017</xref>), presently under clinical investigation for myelofibrosis and glioblastoma. As it is currently the only clinical stage IRAK1 inhibitor with known clinical efficacy and acceptable safety even after prolonged administration (<xref ref-type="bibr" rid="bib90">Singer et al., 2018</xref>), we chose this compound for our functional studies to target IRAK1.</p><p>EPOR forms a heterodimer with β common receptor (βCR), also known as the Tissue-Protective Receptor (TPR) (<xref ref-type="bibr" rid="bib13">Brines et al., 2004</xref>). The endogenous hormone EPO binds the TPR activating signaling cascades with roles in neuroprotection (<xref ref-type="bibr" rid="bib84">Rey et al., 2019</xref>). EPO has a very well understood pharmacological profile, and several variants of erythropoietin lacking hematopoietic effects have been developed and shown to preserve the neuroprotective effects of EPO administration (<xref ref-type="bibr" rid="bib19">Chen et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Patel et al., 2011</xref>).</p><p>KEAP1 is the key repressor of the transcription factor nuclear factor erythroid 2-related factor 2 (NFE2L2), which is involved in response to antioxidants through its transcriptional regulation of inflammatory pathways. Dimethyl fumarate (DMF) is an approved treatment for both multiple sclerosis and psoriasis (<xref ref-type="bibr" rid="bib96">Torkildsen et al., 2016</xref>; <xref ref-type="bibr" rid="bib9">Blair, 2018</xref>). Its administration decreases KEAP1 levels, increases NFE2L2 levels and causes dissociation and nuclear transport of NFE2L2. DMF treatment has proven to be effective and safe in conferring neuroprotection (<xref ref-type="bibr" rid="bib65">Montes Diaz et al., 2018</xref>).</p><p>Since the three candidate proteins targeted by these drug products (IRAK1, EPOR, and KEAP1) all have possible roles mediating inflammation, we chose to proceed with these for functional studies in cells modeling neural inflammatory phenotypes. The other three proteins identified (DNMT1, ICAM1, and ICAM3) may also be interesting targets for future study.</p></sec><sec id="s2-3"><title>Human neural cell cultures exhibit Rett-like phenotypes when MECP2 is silenced</title><p>To analyze the effects of the three selected compounds on a RTT model system, we employed human immortalized primary neural cells silenced for MECP2. We chose to use a human in vitro model system for preliminary validation due to the significant differences in the phenotypes and functions of mouse and human neural cells (<xref ref-type="bibr" rid="bib104">Xu et al., 2018</xref>). Indeed, recent studies reported the use of iPSCs and immortalized glial cells as reliable human models for analyzing specific therapeutic targets for various diseases including autism (<xref ref-type="bibr" rid="bib98">Tsilioni et al., 2020</xref>), neuroinflammation (<xref ref-type="bibr" rid="bib21">Chiavari et al., 2019</xref>; <xref ref-type="bibr" rid="bib95">Timmerman et al., 2018</xref>) and for analyzing the crosstalk of glioma with glial cells (<xref ref-type="bibr" rid="bib36">Henrik Heiland et al., 2019</xref>; <xref ref-type="bibr" rid="bib106">Zeng et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Bier et al., 2020</xref>).</p><p>Since all three selected compounds were associated with changes in neuroinflammation, we first focused on microglia and astrocytes. Loss or impaired function of MECP2 has been reported to affect the functions of glial cells and these changes have been implicated in the pathogenesis of RTT (<xref ref-type="bibr" rid="bib45">Kahanovitch et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Jin et al., 2017</xref>). We first characterized the effects of MECP2 silencing on the phenotypes of microglia (<xref ref-type="fig" rid="fig3">Figure 3</xref>). For these experiments, we transduced the cells with lentivirus vectors expressing control or MECP2 shRNAs. The expression of MECP2 was silenced by over 80% in these cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). MECP2 silencing induced a relative increase in the expression of M1 markers (IL1, and CD86) and a relative decrease of M2 markers (CD206 and IL-13) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), suggesting an increase in neuroinflammation. We also found that MECP2 silencing decreased the phagocytosis of the microglia cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Effects of MECP2 knockdown on neural cell phenotypes.</title><p>Human microglia (<bold>A,B</bold>), NSCs (<bold>C</bold>), astrocytes (<bold>D,E</bold>), and neurons (<bold>E</bold>) were silenced for MECP2 using lentivirus vector. The relative expression of M1 and M2 markers was analyzed in microglia cells using RT-PCR (<bold>A</bold>) and degree of phagocytosis using the pHrodo assay (<bold>B</bold>). NSCs were transduced with lentivirus vectors expressing the differentiation reporters GFAP and MAP2 and were differentiated as described in the methods. Ten days later, luciferase activity was determined (<bold>C</bold>). Astrocytes silenced for MECP2 were analyzed for the expression of EAAT2 using western blot analysis (<bold>D</bold>) and the expression of BDNF mRNA in both MECP2 silenced astrocytes and neurons was determined using RT-PCR (<bold>E</bold>). The results are a representative experiment of three separate tests analyzed in quadruplet. **p&lt;0.01, ***p&lt;0.001,****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Silencing of MECP2 in neural cells.</title><p>Neurons, astrocytes, and microglia cells were transduced with lentivirus vectors expressing a control or MECP2 shRNAs. Following 3 days, the expression of MECP2 and actin were determined using western blot analysis. The results are representative of three experiments with similar results.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Cytotoxic effects of tested compounds.</title><p>Human microglia (<bold>A</bold>), astrocytes (<bold>B</bold>), neurons (<bold>C</bold>), and neuronal stem cells (<bold>D</bold>) were treated with different concentrations of DMF (1, 10, and 50 µM), EPO (10, 30, and 50 ng/ml), and pacrinitib (1 and 10 µM). Following 3 days of treatment, the cells were analyzed for cell death using LDH assay. The results are the means ± SD of six samples for each compound.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig3-figsupp2-v1.tif"/></fig></fig-group><p>We next analyzed the effect of MECP2 silencing on human astrocyte differentiation and functions. For these experiments, neural stem cells (NSCs) were transduced with lentivirus vectors expressing the differentiation reporters, GFP/fLuc GFAP or the mCherry/Luc MAP2. The cells were plated on laminin coated plates and luciferase activity was determined 10 days later. In accordance with previous reports (<xref ref-type="bibr" rid="bib2">Andoh-Noda et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Mok et al., 2020</xref>), we found that MECP2 silenced NSCs displayed preferential expression of the glial differentiation marker (GFAP) with a concomitant decrease in expression of the neuronal differentiation marker (MAP2) (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). The MECP2 silenced astrocytes expressed lower levels of Excitatory Amino Acid Transporter 2 (EAAT2), indicating impaired function of these cells, as was suggested for mouse astrocytes (<xref ref-type="bibr" rid="bib72">Okabe et al., 2012</xref>; <xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>We finally examined the effects of MECP2 silencing on the expression of BDNF in human neurons and astrocytes and found that, as reported for mouse cells (<xref ref-type="bibr" rid="bib16">Chang et al., 2006</xref>; <xref ref-type="bibr" rid="bib55">Li et al., 2012</xref>), MECP2 silencing decreased the expression of BDNF mRNA in both astrocyte and neuronal cultures (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Altogether, these finding indicate that the immortalized human cells employed in this study represent a reliable model for studying MECP2-related pathways and potential treatments.</p></sec><sec id="s2-4"><title>DMF, EPO, and pacritinib differentially abrogate the effects of MECP2 silencing on microglia polarization</title><p>We then analyzed the effects of the three selected compounds, DMF, EPO and pacritinib, on MECP2 silenced cells. We first demonstrated that in the concentrations range we used, none of these compounds exerted a toxic effect on neither microglia cells, astrocytes, primary neuronal cells nor NSCs (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>).</p><p>Control and MECP2 silenced microglia were treated with the DMF, EPO, and pacritinib, and their effects on the relative expression M1 (IL1, TNFα and CD86) and M2 (CD206 and IL-13) markers were determined using RT-PCR. While MECP2 wild-type cells were unchanged by the three compounds, all three abrogated the M1 shift induced by MECP2 silencing, albeit to a different degree (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). EPO exerted the most significant effect, abrogating the effects of MECP2 silencing in all five marker genes (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In contrast, both DMF and pacritinib exerted only partial effects, abrogating the effects of MECP2 silencing in CD206, CD86, and IL-1, but failing to abrogate the effects on IL-13 and TNF-α (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>). We also analyzed the effects on phagocytosis in microglia cells. Treatment of MECP2 silenced cells with DMF exerted a significant increase in the phagocytosis of the silenced cells, whereas EPO and pacritinib did not (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Effects of tested compounds on the polarization of microglial cells.</title><p>Human microglia cells were silenced for MECP2 using lentivirus vectors expressing MECP2 shRNA. Control cells were transduced with lentivirus vectors expressing a control shRNA. After 5 days, the expression of MECP2 was determined by western blot analysis (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Control and silenced cells were treated with EPO 10 ng/ml (<bold>A</bold>), DMF 10 µM (<bold>B</bold>) and pacritinib 10 µM (<bold>C</bold>), and the expression of M1 and M2-associated markers were determined after 72 hr using RT-PCR. MECP2 silenced microglia cells treated with EPO, DMF, or pacritinib were also analyzed for phagocytosis using the pHrodo assay (<bold>D</bold>). MECP2-silenced microglia cells were transduced with lentivirus vectors expressing the NF-kB reporter followed by treatment with EPO, DMF, and pacritinib for 24 hr. Luciferase activity was determined (<bold>E</bold>). The results demonstrate the means ± SD of a representative experiment of three separate tests analyzed in quadruplet. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001,****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig4-v1.tif"/></fig></sec><sec id="s2-5"><title>EPO and DMF inhibit NF-κB activation in MECP2 silenced microglia cells</title><p>Knockdown of MECP2 has been reported to lead to increased NF-κB activity in neuronal and myeloid cells (<xref ref-type="bibr" rid="bib71">O'Driscoll et al., 2015</xref>) and this deregulated activity has been associated with neuroinflammation and decreased dendritic arborization and spine density in a mouse model of RTT (<xref ref-type="bibr" rid="bib52">Kishi et al., 2016</xref>). We therefore examined the ability of our three candidate compounds to abrogate the increased NF-κB activity in MECP2 KD microglia cells. MECP2-silenced microglia cells were transfected with lentivirus vectors expressing the NF-κB luciferase reporter and a constitutively active Renilla luciferase construct (as a transfection control). The cells were treated with EPO, DMF and pacritinib for 24 hr and luciferase activity was determined thereafter. A significant increase in NF-κB-dependent luciferase activation was observed for EPO and DMF in the MECP2-silenced cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), indicating that EPO and DMF were able to downregulate the increased NF-κB activation in MECP2 KD cells.</p></sec><sec id="s2-6"><title>EPO, but not DMF or pacritinib, abrogate improper astrocytic differentiation and astrocyte function in MECP2-silenced neural cells</title><p>Various studies support a non-cell-autonomous effect of astrocytes on neuronal cell functions and contribution of astrocytes to various aspects of Rett syndrome pathogenesis via regulation of glutamate levels, homeostasis, and neuroinflammation (<xref ref-type="bibr" rid="bib45">Kahanovitch et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Maezawa et al., 2009</xref>). As presented in <xref ref-type="fig" rid="fig3">Figure 3C</xref>, MECP2 silencing increased astrocytic differentiation of NSCs at the expense of neuronal differentiation. Treatment of the silenced NSCs with pacritinib or DMF did not have significant effects on markers of neuronal (βIII tubulin) or astrocytic (GFAP) differentiation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In contrast, EPO abrogated the impaired NSC differentiation as reflected by an increase of βIII tubulin and a decrease of GFAP (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In human astrocytes, MECP2 silencing decreased the expression of the glutamate transporter EAAT2 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Treatment of these cells with EPO inhibited the decreased EAAT2 expression, whereas pacritinib and DMF did not have a significant effect (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Effects of tested compounds on the differentiation of NSCs and EAAT2 expression in astrocytes.</title><p>Human NSCs (<bold>A</bold>) and astrocytes (<bold>B</bold>) were silenced for MECP2 using lentivirus vectors expressing MECP2 shRNA. Control cells were transduced with lentivirus vectors expressing a control shRNA. After 5 days, the expression of MECP2 was determined by western blot analysis (<xref ref-type="fig" rid="fig3s1">Figure 3—figure suppplement 1</xref>). (<bold>A</bold>) Control and silenced NSCs were allowed to differentiate for 10 days and the expression of differentiation markers GFAP and βIII tubulin were determined using RT-PCR. (<bold>B</bold>) Silenced astrocytes treated with the different compounds or with medium were analyzed for the expression of EAAT2 using RT-PCR. The results are of a representative experiment of three separate tests analyzed in quadruplet. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001,****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig5-v1.tif"/></fig></sec><sec id="s2-7"><title>DMF and EPO upregulate BDNF expression in MECP2-silenced cells</title><p>BDNF plays important roles in neuronal growth and development and represents a well-recognized transcriptional target of MECP2 (<xref ref-type="bibr" rid="bib18">Chen et al., 2003</xref>). Silencing of <italic>MECP2</italic> decreased BDNF expression in both neurons and astrocytes (<xref ref-type="fig" rid="fig6">Figure 6A–B</xref>). DMF and EPO induced an increase in BDNF mRNA in the silenced neurons (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) and in the silenced astrocytes (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), whereas pacritinib did not exert a significant effect in either. We replicated this experiment in astrocytes, testing DMF and EPI both individually and in combination (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). This showed a modest increase in the level of BDNF in the in the combined treatment, suggesting potentially independent modes of action.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>BDNF expression in neural cells.</title><p>MECP2 expression was silenced in human neurons (<bold>A</bold>) and astrocytes (<bold>B, C</bold>) and BDNF expression was analyzed in cells treated with a medium or the specific tested compounds using both RT-PCR (<bold>A</bold>) and ELISA (<bold>B, C</bold>). The combinatorial effect of EPO and DMF was assessed on BDNF expression in astrocytes (<bold>C</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001,****p&lt;0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig6-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Rett syndrome is a neurodevelopmental disease without evidence of degeneration and thus rescuing MECP2 downstream activity might improve disease pathophysiology even in adulthood (<xref ref-type="bibr" rid="bib28">Faundez et al., 2019</xref>). In murine models, reintroduction of <italic>MECP2</italic> to adult animals led to vast phenotypic improvements (<xref ref-type="bibr" rid="bib35">Guy et al., 2007</xref>). In parallel with approaches aimed at increasing MECP2 levels directly (<xref ref-type="bibr" rid="bib12">Brendel et al., 2011</xref>; <xref ref-type="bibr" rid="bib63">Merritt et al., 2020</xref>; <xref ref-type="bibr" rid="bib79">Przanowski et al., 2018</xref>), accurate mapping of the MECP2 gene network is important to provide additional avenues for intervention, and avoid the toxicity associated with overexpression of MECP2 (<xref ref-type="bibr" rid="bib82">Ramocki et al., 2009</xref>). Here, we have presented a framework for identifying potential drug-gene interactions based on comparative genomics, and validate these interactions in human immortalized primary neural cells. We analyzed phylogenetic profiling across mammals and hundreds of eukaryotes to infer functional links and generated a network of co-evolved genes, identifying known targets such as IRAK1 as well as new candidates such as EPOR. We then mined this network to identify actionable drug targets, prioritizing a list of associated compounds using a combination of strong co-evolutionary evidence of the target proteins and a proven safety profile of approved pharmaceutical compounds (Pacritinib, DMF, and EPO). While we prioritized based on the potential for drug repurposing, our evolutionary analysis could also be used to identify additional targets for drug design. Furthermore, we only performed functional validation 3 of the 33 co-evolved genes associated with approved drugs, leaving others for potential future study.</p><p>We reproduced a number of RTT phenotypes by reducing expression of MECP2 in human neural cell cultures. When treated with the three selected compounds, these phenotypes could all be reversed to different degrees in a cell-dependent manner. While all the compounds restored the polarization of microglia and reduced the hyperactivity of NF-κB signaling in microglia, only DMF abrogated decreased phagocytosis. EPO alone reversed the impaired neuronal/astrocyte differentiation of NSCs. In neurons and astrocytes, DMF and EPO abrogated the inhibitory effect of <italic>MECP2</italic> silencing on BDNF expression and secretion, whereas pacritinib did not have a significant effect.</p><p>The activity of these compounds on microglia polarization and NF-κB activity is mechanistically interesting. Activation of microglia cells has been reported in <italic>MECP2</italic> KO mice (<xref ref-type="bibr" rid="bib107">Zhao et al., 2017</xref>) and has been associated with pathological process in RTT (<xref ref-type="bibr" rid="bib45">Kahanovitch et al., 2019</xref>). An MECP2 KO mouse model also implicated NF-κB signaling and IRAK1 as important mediators of the neuroinflammatory response in RTT (<xref ref-type="bibr" rid="bib52">Kishi et al., 2016</xref>). While the mechanisms involved in the reversing effects of these three compounds remains to be determined, NF-κB signaling downstream of MECP2 is an attractive candidate (<xref ref-type="fig" rid="fig7">Figure 7</xref>). EPOR and KEAP1 have also been implicated as NF-κB modulators involved in the inflammatory response. The endogenous hormone EPO binds the TPR to suppresses inflammatory cytokines in immune cells, a process which involves inhibition of the NF-κB pathway through GSK3β (<xref ref-type="bibr" rid="bib76">Patel et al., 2011</xref>). NFE2L2, usually bound by KEAP1, also has a direct cytoplasmic role in modulating NF-κB signaling through degradation of IκB and nuclear translocation of NF-κB (<xref ref-type="bibr" rid="bib31">Ganesh Yerra et al., 2013</xref>). The three compounds tested all inhibited NF-κB-dependent luciferase activation in microglia cells to a certain extent, validating their involvement in this context.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>A model of MECP2 network genes converging on NF-κB signaling.</title><p>(<bold>A</bold>) We propose that reduced MECP2 levels could lead to increase in ICAM1, ICAM3, IRAK1, and KEAP1 levels, and a decrease of EPOR levels within the tissue-protective receptor. (<bold>B</bold>) IRAK-1 plays a role in NF-κB activation through IKK activation, which leads to IκB phosphorylation and subsequent degradation, NF-κB nuclear translocation and the expression of its pro-inflammatory target genes. KEAP1 binds NFE2L2 and prevents its nuclear localization. NFE2L2 target genes inhibits NF-κB signaling through a non-transcriptional mechanism involving degradation of IκBα. EPO binds EPOR and enhances the activation of Akt, resulting in inhibition of GSK-3β and inhibition of NF-κB nuclear transport.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-fig7-v1.tif"/></fig><p>In addition to the inflammatory effect, we found that <italic>MECP2</italic> silencing decreased the neuronal while increasing the astrocytic differentiation of NSCs. However, human astrocyte function was impaired in the MECP2 silenced cells and these cells expressed lower levels of the glutamate transporter EAAT2. The signaling pathways involved in these effects of EPO are not fully characterized; however, NF-κB has been recently reported to regulate EAAT2 expression in astrocytes (<xref ref-type="bibr" rid="bib102">Wei et al., 2019</xref>).</p><p>Finally, we found that both DMF and EPO rescued the decreased BDNF expression in MECP2-silenced microglia and astrocytes. Indeed, both NF-κB and NFE2L2 pathways have been reported to be associated with the regulation of BDNF expression (<xref ref-type="bibr" rid="bib15">Caviedes et al., 2017</xref>; <xref ref-type="bibr" rid="bib66">Nair and Wong-Riley, 2016</xref>). Thus, DMF can increase BDNF levels through an increase in NFE2L2, which binds the <italic>BDNF</italic> promotor and acts as a transcriptional activator (<xref ref-type="bibr" rid="bib66">Nair and Wong-Riley, 2016</xref>). EPO administration activates the STAT3 signaling pathway (<xref ref-type="bibr" rid="bib84">Rey et al., 2019</xref>), which can in turn elevate BDNF expression (<xref ref-type="bibr" rid="bib20">Chen et al., 2016</xref>).</p><p>While the strong evolutionary linkage of our target proteins to MECP2 strongly suggest that they are mediating the reversal of MECP2 silencing phenotypes by their associated drugs, we have not ruled out the possibility for alternative action of these drugs or joint action upon our involving other protein targets. A good example of this are the HDAC chromatin modifiers, a group of genes which did not come up as specifically linked to MECP2 in our evolutionary analysis but are well-known interactors. HDACs play a crucial role in neuronal development, and MECP2-mediated gene repression occurs mainly through HDAC recruitment via the Sin3a and NCoR complexes (<xref ref-type="bibr" rid="bib59">Lyst et al., 2013</xref>; <xref ref-type="bibr" rid="bib25">Ebert et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Nan et al., 1998</xref>). HDACs have been suggested as therapeutic targets for Rett Syndrome (<xref ref-type="bibr" rid="bib89">Shukla and Tekwani, 2020</xref>) and HDAC6 inhibition has been linked to improved BDNF trafficking in a Rett mouse model (<xref ref-type="bibr" rid="bib103">Xu et al., 2014</xref>). Importantly, one of the compounds we examined, DMF, can reduce HDAC1/2/4 expression in rat astrocytes (<xref ref-type="bibr" rid="bib46">Kalinin et al., 2013</xref>), and EPO can promote phosphorylation of HDAC5 in rat hippocampal neurons (<xref ref-type="bibr" rid="bib44">Jo et al., 2016</xref>). It is thus plausible that HDAC inhibition mediates the effects we observe for these drugs, at least in part. However, the effects on HDAC activity are not the principal mechanisms of action of either of the proposed compounds (<xref ref-type="bibr" rid="bib46">Kalinin et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Jo et al., 2016</xref>), nor do they have established interactions with the HDAC most implicated in RTT biology (HDAC6). Future studies should investigate if any of the MECP2-rescuing activities of these drugs act through HDACs in concert with or independent of the target proteins identified here.</p><p>In summary, EPO, DMF and pacritinib act differentially on MECP2-silenced NSCs, microglia and astrocytes, providing a preliminary validation of our approach. The investigation into specific drug effects and mechanisms of actions are important areas for future studies, as are drug combination assays and in-vivo studies of EPO, DMF and pacritinib using MECP2 KO mice. These will be to assess whether any of the identified drugs can be further be explored for clinical use.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mapping MECP2 conservation along 1028 eukaryotic species and identifying correlated genes</title><p>We used the pipeline we described in <xref ref-type="bibr" rid="bib97">Tsaban et al., 2021</xref> to calculate the Normalized Phylogenetic Profile (NPP) of 1028 eukaryotic species and rank genes based on their evolutionary similarity to MECP2. Briefly, 20,192 human proteins (one representative protein sequence per gene) were downloaded from UniProt reference proteomes (June 2018 release) (<xref ref-type="bibr" rid="bib5">Bateman and UniProt Consortium, 2019</xref>). We used the Uniprot canonical isoform for each gene. For the 29 genes with more than one canonical isoform, we selected the longest isoform to maximize sequence information. The proteins were searched with BLASTP (<xref ref-type="bibr" rid="bib14">Camacho et al., 2009</xref>) against the proteomes of the 1028 eukaryotes. A bit-score of 20.4, corresponding to a BLAST e-value of 0.05, was set as a minimal similarity threshold. The top scoring protein in each organism was selected. The bit-scores were normalized to protein length and phylogenetic distance from humans. The output is a matrix P of size 20,242 x 1028 where each entry Pab is the best BLASTP bit score between a human protein sequence ‘a’ and the top result in organism ‘b’. The Pearson correlation was calculated for each profile with the MECP2 profile. The top 200 genes in all eukaryotes were selected as the E200 group for further analysis. This procedure was repeated using only the 51 mammal species, and the top 200 genes in were selected as the M200 group for further analysis.</p></sec><sec id="s4-2"><title>Filtering genes with drug interactions and constructing protein network</title><p>Drug gene interactions were collected from DGIdb (<xref ref-type="bibr" rid="bib22">Cotto et al., 2018</xref>) and from Open Targets (<xref ref-type="bibr" rid="bib73">Oxford Academic, 2019</xref>). Drugs at any stage of development were included in the search as long as the interaction with the target gene had known directionality (e.g. inhibitory, activating). Drug-gene interactions were validated through a literature review and known gene-gene interactions were collected from STRING (<xref ref-type="bibr" rid="bib92">Szklarczyk et al., 2019</xref>). Network diagram was constructed using STRING and Cytoscape (<xref ref-type="bibr" rid="bib58">Lopes et al., 2011</xref>).</p></sec><sec id="s4-3"><title>Synteny and co-localization analysis</title><p>Gene locations were retrieved from BioMart (<xref ref-type="bibr" rid="bib48">Kasprzyk, 2011</xref>), the NCBI genome data viewer (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>), and Genomicus (<xref ref-type="bibr" rid="bib70">Nguyen et al., 2018</xref>; <xref ref-type="fig" rid="fig3">Figure 3A</xref>). Synteny in ancestral species was obtained from Genomicus (<xref ref-type="bibr" rid="bib70">Nguyen et al., 2018</xref>). Intra-chromosomal Hi-C contact heatmaps and TAD borders were collected from the 3D Genome Browser (<xref ref-type="bibr" rid="bib101">Wang et al., 2018</xref>), using GM12878 cell data from the high-resolution Hi-C dataset of <xref ref-type="bibr" rid="bib83">Rao et al., 2014</xref>.</p></sec><sec id="s4-4"><title>Neural cell cultures</title><p>Immortalized human microglial cells and astrocytes were obtained from Applied Biological Material (Richmond, BC, Canada). Human NSCs (H9, hESC-derived) (ReNcell) were obtained from Invitrogen, Merck (Germany). Human neurons were obtained from ScienCell (Carlsbad, CA, USA). All cells employed in this study were tested for mycoplasma contamination (Mycoplasma PCR Detection Kit) and found negative.</p></sec><sec id="s4-5"><title>Transduction of neural cells</title><p>Lentivirus vectors (System Biosciences, Mountain View, CA, USA) expressing the MECP2 or control shRNAs and the reporters GFP/fLuc GFAP, mCherry/Luc MAP2 and NF-kB luciferase were packaged and used to transduce the cells according to the manufacturer's protocol and as previously described (<xref ref-type="bibr" rid="bib33">Giladi et al., 2015</xref>).</p></sec><sec id="s4-6"><title>NSC differentiation</title><p>Human NSCs were maintained as spheroids in an NSC maintenance medium containing fibroblast growth factor 2 (FGF-2) and an epidermal growth factor (EGF, 20 ng/ml) on laminin-coated flasks. For differentiation, the cells were maintained in NSC maintenance medium without FGF-2 and EGF and neuronal and glial differentiation were observed.</p></sec><sec id="s4-7"><title>Microglia polarization</title><p>Human microglia cells were silenced for MECP2 using lentivirus vectors expressing MECP2 or control shRNAs. After 5e days, the expression of MECP2 was determined by western blot analysis and cells exhibiting a decrease of at least 80% were employed in further studies. Control and silenced cells were treated with the specific compounds and the expression of M1- and M2-associated markers were determined after 72 hr using RT-PCR. All experiments were done in triplicates and were repeated three times.</p></sec><sec id="s4-8"><title>Cytotoxicity assay</title><p>Cells were treated with different concentrations of DMF (1 10 and 50 mM), EPO (10, 30 and 50 ng/ml), and Pacritinib (1 and 10 mM). Following 3 days of treatment, the cells were analyzed for cell death using LDH assay. The results are presented as the means ± SD of six samples for each compound.</p></sec><sec id="s4-9"><title>Western blot analysis</title><p>Cell pellet preparation and Western blot analyses were performed as previously described (<xref ref-type="bibr" rid="bib57">Lomonaco et al., 2009</xref>). Equal loading was verified using an anti-β-actin or tubulin antibodies as described (<xref ref-type="bibr" rid="bib33">Giladi et al., 2015</xref>; <xref ref-type="bibr" rid="bib7">Bier et al., 2018</xref>).</p></sec><sec id="s4-10"><title>Real-time PCR</title><p>Total RNA was extracted using RNeasy midi kit according to the manufacturer’s instructions (Qiagen, Frederick, MD, USA). Reverse transcription reaction was carried out using 2 μg total RNA (<xref ref-type="bibr" rid="bib7">Bier et al., 2018</xref>). The primer sequences are described in the supplementary files (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>).</p></sec><sec id="s4-11"><title>Phagocytosis analysis</title><p>Human microglial cells were silenced for MECP2. Phagocytosis was determined using the pHrodo Green zymosan bioparticle assay (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Briefly, microglia were incubated with a solution of pHrodo Green zymosan bioparticles in Live Cell Imaging Solution (0.5 mg/ml) for 2 hr. Phagocytosis was determined using a fluorescence plate reader at Ex/Em 509/533.</p></sec><sec id="s4-12"><title>Luciferase activity</title><p>The firefly luciferase activity of the NF-kB, GFAP and MAP two activities and the control Renilla luciferase activity were analyzed using the Dual-Luciferase Reporter Assay System (Promega Corporation).</p></sec><sec id="s4-13"><title>Statistical analysis for cell assays</title><p>The results are presented as the mean values ± SD. Data were analyzed using a Student's <italic>t</italic>-test with correction for data sets with unequal variances (Welch's unequal variances <italic>t</italic>-test).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Dr. Yaron Daniely and the Yissum team for being a major driving force for this project. We thank Dr. Liana Patt and the Integra Holdings team for their support. We thank Dr. Hae Kyung Lee and Susan Finniss for their technical support. Figures include vector images designed by Freepik. We thank Dr. Amir Eden and Prof. Yinon Ben Neriah for their insight and comments. Funding: This project was supported by an Israel Science Foundation grant 1591/19 to YT and by Integra Holdings. Additional support to BPB and IU came from a grant from the Beethoven Foundation.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Software, Formal analysis, Investigation, Visualization, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Software, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Supervision, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Genes most co-evolved with MECP2.</title></caption><media mime-subtype="octet-stream" mimetype="application" xlink:href="elife-67085-supp1-v1.csv"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>STRING GO-term enrichment of the E200 set.</title></caption><media mime-subtype="plain" mimetype="text" xlink:href="elife-67085-supp2-v1.txt"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>RT-PCR primer sequences.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-67085-supp3-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-67085-transrepform-v1.bpb.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The phylogenetic data required to reproduce the analysis are openly available at Zenodo [<ext-link ext-link-type="uri" xlink:href="https://zenodo.org/record/4464120#.YEoFpHmxVPY">https://zenodo.org/record/4464120#.YEoFpHmxVPY</ext-link>]. Code used for the analysis is openly available through Github <ext-link ext-link-type="uri" xlink:href="https://github.com/GuIrene/MECP2_phylogeny">https://github.com/GuIrene/MECP2_phylogeny</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad">https://archive.softwareheritage.org/swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad</ext-link>).</p><p>The following previously published dataset was used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>D</given-names></name><name><surname>Tsaban</surname><given-names>T</given-names></name><name><surname>Bloch</surname><given-names>I</given-names></name><name><surname>Sharon</surname><given-names>E</given-names></name><name><surname>Tabach</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>CladeOScope: elucidating functional interactions via a clade co-evolution prism</data-title><source>Zenodo</source><pub-id assigning-authority="Zenodo" pub-id-type="doi">10.5281/zenodo.4464120</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname> <given-names>RE</given-names></name><name><surname>Van den Veyver</surname> <given-names>IB</given-names></name><name><surname>Wan</surname> <given-names>M</given-names></name><name><surname>Tran</surname> <given-names>CQ</given-names></name><name><surname>Francke</surname> <given-names>U</given-names></name><name><surname>Zoghbi</surname> <given-names>HY</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2</article-title><source>Nature Genetics</source><volume>23</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1038/13810</pub-id><pub-id pub-id-type="pmid">10508514</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andoh-Noda</surname> <given-names>T</given-names></name><name><surname>Akamatsu</surname> <given-names>W</given-names></name><name><surname>Miyake</surname> <given-names>K</given-names></name><name><surname>Matsumoto</surname> <given-names>T</given-names></name><name><surname>Yamaguchi</surname> <given-names>R</given-names></name><name><surname>Sanosaka</surname> <given-names>T</given-names></name><name><surname>Okada</surname> <given-names>Y</given-names></name><name><surname>Kobayashi</surname> <given-names>T</given-names></name><name><surname>Ohyama</surname> <given-names>M</given-names></name><name><surname>Nakashima</surname> <given-names>K</given-names></name><name><surname>Kurosawa</surname> <given-names>H</given-names></name><name><surname>Kubota</surname> <given-names>T</given-names></name><name><surname>Okano</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Differentiation of multipotent neural stem cells derived from rett syndrome patients is biased toward the astrocytic lineage</article-title><source>Molecular Brain</source><volume>8</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s13041-015-0121-2</pub-id><pub-id pub-id-type="pmid">26012557</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arkadir</surname> <given-names>D</given-names></name><name><surname>Lossos</surname> <given-names>A</given-names></name><name><surname>Rahat</surname> <given-names>D</given-names></name><name><surname>Abu Snineh</surname> <given-names>M</given-names></name><name><surname>Schueler-Furman</surname> <given-names>O</given-names></name><name><surname>Nitschke</surname> <given-names>S</given-names></name><name><surname>Minassian</surname> <given-names>BA</given-names></name><name><surname>Sadaka</surname> <given-names>Y</given-names></name><name><surname>Lerer</surname> <given-names>I</given-names></name><name><surname>Tabach</surname> <given-names>Y</given-names></name><name><surname>Meiner</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>MYORG</italic> is associated with recessive primary familial brain calcification</article-title><source>Annals of Clinical and Translational Neurology</source><volume>6</volume><fpage>106</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1002/acn3.684</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avidor-Reiss</surname> <given-names>T</given-names></name><name><surname>Maer</surname> <given-names>AM</given-names></name><name><surname>Koundakjian</surname> <given-names>E</given-names></name><name><surname>Polyanovsky</surname> <given-names>A</given-names></name><name><surname>Keil</surname> <given-names>T</given-names></name><name><surname>Subramaniam</surname> <given-names>S</given-names></name><name><surname>Zuker</surname> <given-names>CS</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Decoding cilia function: defining specialized genes required for compartmentalized cilia biogenesis</article-title><source>Cell</source><volume>117</volume><fpage>527</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(04)00412-x</pub-id><pub-id pub-id-type="pmid">15137945</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname> <given-names>A</given-names></name><collab>UniProt Consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>UniProt: a worldwide hub of protein knowledge</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D506</fpage><lpage>D515</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1049</pub-id><pub-id pub-id-type="pmid">30395287</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Ari Fuchs</surname> <given-names>S</given-names></name><name><surname>Lieder</surname> <given-names>I</given-names></name><name><surname>Stelzer</surname> <given-names>G</given-names></name><name><surname>Mazor</surname> <given-names>Y</given-names></name><name><surname>Buzhor</surname> <given-names>E</given-names></name><name><surname>Kaplan</surname> <given-names>S</given-names></name><name><surname>Bogoch</surname> <given-names>Y</given-names></name><name><surname>Plaschkes</surname> <given-names>I</given-names></name><name><surname>Shitrit</surname> <given-names>A</given-names></name><name><surname>Rappaport</surname> <given-names>N</given-names></name><name><surname>Kohn</surname> <given-names>A</given-names></name><name><surname>Edgar</surname> <given-names>R</given-names></name><name><surname>Shenhav</surname> <given-names>L</given-names></name><name><surname>Safran</surname> <given-names>M</given-names></name><name><surname>Lancet</surname> <given-names>D</given-names></name><name><surname>Guan-Golan</surname> <given-names>Y</given-names></name><name><surname>Warshawsky</surname> <given-names>D</given-names></name><name><surname>Shtrichman</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>GeneAnalytics: an integrative gene set analysis tool for next generation sequencing, RNAseq and microarray data</article-title><source>OMICS: A Journal of Integrative Biology</source><volume>20</volume><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1089/omi.2015.0168</pub-id><pub-id pub-id-type="pmid">26983021</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bier</surname> <given-names>A</given-names></name><name><surname>Berenstein</surname> <given-names>P</given-names></name><name><surname>Kronfeld</surname> <given-names>N</given-names></name><name><surname>Morgoulis</surname> <given-names>D</given-names></name><name><surname>Ziv-Av</surname> <given-names>A</given-names></name><name><surname>Goldstein</surname> <given-names>H</given-names></name><name><surname>Kazimirsky</surname> <given-names>G</given-names></name><name><surname>Cazacu</surname> <given-names>S</given-names></name><name><surname>Meir</surname> <given-names>R</given-names></name><name><surname>Popovtzer</surname> <given-names>R</given-names></name><name><surname>Dori</surname> <given-names>A</given-names></name><name><surname>Brodie</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy</article-title><source>Biomaterials</source><volume>174</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.04.055</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bier</surname> <given-names>A</given-names></name><name><surname>Hong</surname> <given-names>X</given-names></name><name><surname>Cazacu</surname> <given-names>S</given-names></name><name><surname>Goldstein</surname> <given-names>H</given-names></name><name><surname>Rand</surname> <given-names>D</given-names></name><name><surname>Xiang</surname> <given-names>C</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Ben-Asher</surname> <given-names>HW</given-names></name><name><surname>Attia</surname> <given-names>M</given-names></name><name><surname>Brodie</surname> <given-names>A</given-names></name><name><surname>She</surname> <given-names>R</given-names></name><name><surname>Poisson</surname> <given-names>LM</given-names></name><name><surname>Brodie</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>miR-504 modulates the stemness and mesenchymal transition of glioma stem cells and their interaction with microglia via delivery by extracellular vesicles</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41419-020-03088-3</pub-id><pub-id pub-id-type="pmid">33093452</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname> <given-names>HA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dimethyl fumarate: a review in moderate to severe plaque psoriasis</article-title><source>Drugs</source><volume>78</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1007/s40265-017-0854-6</pub-id><pub-id pub-id-type="pmid">29236231</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch</surname> <given-names>I</given-names></name><name><surname>Sherill-Rofe</surname> <given-names>D</given-names></name><name><surname>Stupp</surname> <given-names>D</given-names></name><name><surname>Unterman</surname> <given-names>I</given-names></name><name><surname>Beer</surname> <given-names>H</given-names></name><name><surname>Sharon</surname> <given-names>E</given-names></name><name><surname>Tabach</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Optimization of co-evolution analysis through phylogenetic profiling reveals pathway-specific signals</article-title><source>Bioinformatics</source><volume>36</volume><fpage>4116</fpage><lpage>4125</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa281</pub-id><pub-id pub-id-type="pmid">32353123</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname> <given-names>M</given-names></name><name><surname>Sharon</surname> <given-names>E</given-names></name><name><surname>Unterman</surname> <given-names>I</given-names></name><name><surname>Miller</surname> <given-names>M</given-names></name><name><surname>Shtern</surname> <given-names>AM</given-names></name><name><surname>Benenson</surname> <given-names>S</given-names></name><name><surname>Vainstein</surname> <given-names>A</given-names></name><name><surname>Tabach</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>ACE2 Co-evolutionary pattern suggests targets for pharmaceutical intervention in the COVID-19 pandemic</article-title><source>iScience</source><volume>23</volume><elocation-id>101384</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2020.101384</pub-id><pub-id pub-id-type="pmid">32738617</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brendel</surname> <given-names>C</given-names></name><name><surname>Belakhov</surname> <given-names>V</given-names></name><name><surname>Werner</surname> <given-names>H</given-names></name><name><surname>Wegener</surname> <given-names>E</given-names></name><name><surname>Gärtner</surname> <given-names>J</given-names></name><name><surname>Nudelman</surname> <given-names>I</given-names></name><name><surname>Baasov</surname> <given-names>T</given-names></name><name><surname>Huppke</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Readthrough of nonsense mutations in rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model</article-title><source>Journal of Molecular Medicine</source><volume>89</volume><fpage>389</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1007/s00109-010-0704-4</pub-id><pub-id pub-id-type="pmid">21120444</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brines</surname> <given-names>M</given-names></name><name><surname>Grasso</surname> <given-names>G</given-names></name><name><surname>Fiordaliso</surname> <given-names>F</given-names></name><name><surname>Sfacteria</surname> <given-names>A</given-names></name><name><surname>Ghezzi</surname> <given-names>P</given-names></name><name><surname>Fratelli</surname> <given-names>M</given-names></name><name><surname>Latini</surname> <given-names>R</given-names></name><name><surname>Xie</surname> <given-names>QW</given-names></name><name><surname>Smart</surname> <given-names>J</given-names></name><name><surname>Su-Rick</surname> <given-names>CJ</given-names></name><name><surname>Pobre</surname> <given-names>E</given-names></name><name><surname>Diaz</surname> <given-names>D</given-names></name><name><surname>Gomez</surname> <given-names>D</given-names></name><name><surname>Hand</surname> <given-names>C</given-names></name><name><surname>Coleman</surname> <given-names>T</given-names></name><name><surname>Cerami</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor</article-title><source>PNAS</source><volume>101</volume><fpage>14907</fpage><lpage>14912</lpage><pub-id pub-id-type="doi">10.1073/pnas.0406491101</pub-id><pub-id pub-id-type="pmid">15456912</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camacho</surname> <given-names>C</given-names></name><name><surname>Coulouris</surname> <given-names>G</given-names></name><name><surname>Avagyan</surname> <given-names>V</given-names></name><name><surname>Ma</surname> <given-names>N</given-names></name><name><surname>Papadopoulos</surname> <given-names>J</given-names></name><name><surname>Bealer</surname> <given-names>K</given-names></name><name><surname>Madden</surname> <given-names>TL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>BLAST+: architecture and applications</article-title><source>BMC Bioinformatics</source><volume>10</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1186/1471-2105-10-421</pub-id><pub-id pub-id-type="pmid">20003500</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caviedes</surname> <given-names>A</given-names></name><name><surname>Lafourcade</surname> <given-names>C</given-names></name><name><surname>Soto</surname> <given-names>C</given-names></name><name><surname>Wyneken</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>BDNF/NF-κB signaling in the neurobiology of depression</article-title><source>Current Pharmaceutical Design</source><volume>23</volume><fpage>3154</fpage><lpage>3163</lpage><pub-id pub-id-type="doi">10.2174/1381612823666170111141915</pub-id><pub-id pub-id-type="pmid">28078988</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>Q</given-names></name><name><surname>Khare</surname> <given-names>G</given-names></name><name><surname>Dani</surname> <given-names>V</given-names></name><name><surname>Nelson</surname> <given-names>S</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression</article-title><source>Neuron</source><volume>49</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2005.12.027</pub-id><pub-id pub-id-type="pmid">16446138</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname> <given-names>HT</given-names></name><name><surname>Zoghbi</surname> <given-names>HY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>MeCP2: only 100% will do<italic>Nat</italic></article-title><source>NeuroSci</source><volume>15</volume><fpage>176</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/nn.3027</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>WG</given-names></name><name><surname>Chang</surname> <given-names>Q</given-names></name><name><surname>Lin</surname> <given-names>Y</given-names></name><name><surname>Meissner</surname> <given-names>A</given-names></name><name><surname>West</surname> <given-names>AE</given-names></name><name><surname>Griffith</surname> <given-names>EC</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2</article-title><source>Science</source><volume>302</volume><fpage>885</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1126/science.1086446</pub-id><pub-id pub-id-type="pmid">14593183</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Carbamylated erythropoietin: a prospective drug candidate for neuroprotection</article-title><source>Biochemistry Insights</source><volume>8</volume><elocation-id>BCI.S30753</elocation-id><pub-id pub-id-type="doi">10.4137/BCI.S30753</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Liang</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>Z</given-names></name><name><surname>An</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>W</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autocrine activity of BDNF induced by the STAT3 signaling pathway causes prolonged TrkB activation and promotes human non-small-cell lung Cancer proliferation</article-title><source>Scientific Reports</source><volume>6</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/srep30404</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiavari</surname> <given-names>M</given-names></name><name><surname>Ciotti</surname> <given-names>GMP</given-names></name><name><surname>Navarra</surname> <given-names>P</given-names></name><name><surname>Lisi</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pro-Inflammatory activation of A new immortalized human microglia cell line</article-title><source>Brain Sciences</source><volume>9</volume><elocation-id>111</elocation-id><pub-id pub-id-type="doi">10.3390/brainsci9050111</pub-id><pub-id pub-id-type="pmid">31096716</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotto</surname> <given-names>KC</given-names></name><name><surname>Wagner</surname> <given-names>AH</given-names></name><name><surname>Feng</surname> <given-names>YY</given-names></name><name><surname>Kiwala</surname> <given-names>S</given-names></name><name><surname>Coffman</surname> <given-names>AC</given-names></name><name><surname>Spies</surname> <given-names>G</given-names></name><name><surname>Wollam</surname> <given-names>A</given-names></name><name><surname>Spies</surname> <given-names>NC</given-names></name><name><surname>Griffith</surname> <given-names>OL</given-names></name><name><surname>Griffith</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>DGIdb 3.0: a redesign and expansion of the drug-gene interaction database</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D1068</fpage><lpage>D1073</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1143</pub-id><pub-id pub-id-type="pmid">29156001</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Date</surname> <given-names>SV</given-names></name><name><surname>Marcotte</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Discovery of uncharacterized cellular systems by genome-wide analysis of functional linkages</article-title><source>Nature Biotechnology</source><volume>21</volume><fpage>1055</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1038/nbt861</pub-id><pub-id pub-id-type="pmid">12923548</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname> <given-names>G</given-names></name><name><surname>Jaimovich</surname> <given-names>A</given-names></name><name><surname>Collins</surname> <given-names>SR</given-names></name><name><surname>Seki</surname> <given-names>A</given-names></name><name><surname>Meyer</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Systematic discovery of human gene function and principles of modular organization through phylogenetic profiling</article-title><source>Cell Reports</source><volume>10</volume><fpage>993</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.01.025</pub-id><pub-id pub-id-type="pmid">25683721</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname> <given-names>DH</given-names></name><name><surname>Gabel</surname> <given-names>HW</given-names></name><name><surname>Robinson</surname> <given-names>ND</given-names></name><name><surname>Kastan</surname> <given-names>NR</given-names></name><name><surname>Hu</surname> <given-names>LS</given-names></name><name><surname>Cohen</surname> <given-names>S</given-names></name><name><surname>Navarro</surname> <given-names>AJ</given-names></name><name><surname>Lyst</surname> <given-names>MJ</given-names></name><name><surname>Ekiert</surname> <given-names>R</given-names></name><name><surname>Bird</surname> <given-names>AP</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR</article-title><source>Nature</source><volume>499</volume><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nature12348</pub-id><pub-id pub-id-type="pmid">23770587</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname> <given-names>JA</given-names></name><name><surname>Wu</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Phylogenetic analysis and gene functional predictions: phylogenomics in action</article-title><source>Theoretical Population Biology</source><volume>61</volume><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1006/tpbi.2002.1594</pub-id><pub-id pub-id-type="pmid">12167367</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enault</surname> <given-names>F</given-names></name><name><surname>Suhre</surname> <given-names>K</given-names></name><name><surname>Poirot</surname> <given-names>O</given-names></name><name><surname>Abergel</surname> <given-names>C</given-names></name><name><surname>Claverie</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Phydbac2: improved inference of gene function using interactive phylogenomic profiling and chromosomal location analysis</article-title><source>Nucleic Acids Research</source><volume>32</volume><fpage>W336</fpage><lpage>W339</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh365</pub-id><pub-id pub-id-type="pmid">15215406</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faundez</surname> <given-names>V</given-names></name><name><surname>Wynne</surname> <given-names>M</given-names></name><name><surname>Crocker</surname> <given-names>A</given-names></name><name><surname>Tarquinio</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Molecular systems biology of neurodevelopmental disorders, rett syndrome as an archetype</article-title><source>Frontiers in Integrative Neuroscience</source><volume>13</volume><elocation-id>30</elocation-id><pub-id pub-id-type="doi">10.3389/fnint.2019.00030</pub-id><pub-id pub-id-type="pmid">31379529</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritz</surname> <given-names>AJ</given-names></name><name><surname>Sehgal</surname> <given-names>N</given-names></name><name><surname>Pliss</surname> <given-names>A</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Berezney</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chromosome territories and the global regulation of the genome<italic>Genes Chromosom</italic></article-title><source>Cancer</source><volume>58</volume><fpage>407</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1002/gcc.22732</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gadalla</surname> <given-names>KKE</given-names></name><name><surname>Bailey</surname> <given-names>MES</given-names></name><name><surname>Spike</surname> <given-names>RC</given-names></name><name><surname>Ross</surname> <given-names>PD</given-names></name><name><surname>Woodard</surname> <given-names>KT</given-names></name><name><surname>Kalburgi</surname> <given-names>SN</given-names></name><name><surname>Bachaboina</surname> <given-names>L</given-names></name><name><surname>Deng</surname> <given-names>JV</given-names></name><name><surname>West</surname> <given-names>AE</given-names></name><name><surname>Samulski</surname> <given-names>RJ</given-names></name><name><surname>Gray</surname> <given-names>SJ</given-names></name><name><surname>Cobb</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice</article-title><source>Molecular Therapy</source><volume>21</volume><fpage>18</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/mt.2012.200</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganesh Yerra</surname> <given-names>V</given-names></name><name><surname>Negi</surname> <given-names>G</given-names></name><name><surname>Sharma</surname> <given-names>SS</given-names></name><name><surname>Kumar</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathy</article-title><source>Redox Biology</source><volume>1</volume><fpage>394</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2013.07.005</pub-id><pub-id pub-id-type="pmid">24024177</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname> <given-names>SK</given-names></name><name><surname>Lioy</surname> <given-names>DT</given-names></name><name><surname>Cheval</surname> <given-names>H</given-names></name><name><surname>McGann</surname> <given-names>JC</given-names></name><name><surname>Bissonnette</surname> <given-names>JM</given-names></name><name><surname>Murtha</surname> <given-names>MJ</given-names></name><name><surname>Foust</surname> <given-names>KD</given-names></name><name><surname>Kaspar</surname> <given-names>BK</given-names></name><name><surname>Bird</surname> <given-names>A</given-names></name><name><surname>Mandel</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of rett syndrome</article-title><source>Journal of Neuroscience</source><volume>33</volume><fpage>13612</fpage><lpage>13620</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1854-13.2013</pub-id><pub-id pub-id-type="pmid">23966684</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giladi</surname> <given-names>ND</given-names></name><name><surname>Ziv-Av</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>HK</given-names></name><name><surname>Finniss</surname> <given-names>S</given-names></name><name><surname>Cazacu</surname> <given-names>S</given-names></name><name><surname>Xiang</surname> <given-names>C</given-names></name><name><surname>Ben-Asher</surname> <given-names>HW</given-names></name><name><surname>deCarvalho</surname> <given-names>A</given-names></name><name><surname>Mikkelsen</surname> <given-names>T</given-names></name><name><surname>Poisson</surname> <given-names>L</given-names></name><name><surname>Brodie</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop</article-title><source>Oncotarget</source><volume>6</volume><fpage>22680</fpage><lpage>22697</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4205</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glaze</surname> <given-names>DG</given-names></name><name><surname>Neul</surname> <given-names>JL</given-names></name><name><surname>Kaufmann</surname> <given-names>WE</given-names></name><name><surname>Berry-Kravis</surname> <given-names>E</given-names></name><name><surname>Condon</surname> <given-names>S</given-names></name><name><surname>Stoms</surname> <given-names>G</given-names></name><name><surname>Oosterholt</surname> <given-names>S</given-names></name><name><surname>Della Pasqua</surname> <given-names>O</given-names></name><name><surname>Glass</surname> <given-names>L</given-names></name><name><surname>Jones</surname> <given-names>NE</given-names></name><name><surname>Percy</surname> <given-names>AK</given-names></name><collab>Rett 002 Study Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Double-blind, randomized, placebo-controlled study of trofinetide in pediatric rett syndrome</article-title><source>Neurology</source><volume>92</volume><fpage>e1912</fpage><lpage>e1925</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000007316</pub-id><pub-id pub-id-type="pmid">30918097</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname> <given-names>J</given-names></name><name><surname>Gan</surname> <given-names>J</given-names></name><name><surname>Selfridge</surname> <given-names>J</given-names></name><name><surname>Cobb</surname> <given-names>S</given-names></name><name><surname>Bird</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Reversal of neurological defects in a mouse model of rett syndrome</article-title><source>Science</source><volume>315</volume><fpage>1143</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1126/science.1138389</pub-id><pub-id pub-id-type="pmid">17289941</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrik Heiland</surname> <given-names>D</given-names></name><name><surname>Ravi</surname> <given-names>VM</given-names></name><name><surname>Behringer</surname> <given-names>SP</given-names></name><name><surname>Frenking</surname> <given-names>JH</given-names></name><name><surname>Wurm</surname> <given-names>J</given-names></name><name><surname>Joseph</surname> <given-names>K</given-names></name><name><surname>Garrelfs</surname> <given-names>NWC</given-names></name><name><surname>Strähle</surname> <given-names>J</given-names></name><name><surname>Heynckes</surname> <given-names>S</given-names></name><name><surname>Grauvogel</surname> <given-names>J</given-names></name><name><surname>Franco</surname> <given-names>P</given-names></name><name><surname>Mader</surname> <given-names>I</given-names></name><name><surname>Schneider</surname> <given-names>M</given-names></name><name><surname>Potthoff</surname> <given-names>AL</given-names></name><name><surname>Delev</surname> <given-names>D</given-names></name><name><surname>Hofmann</surname> <given-names>UG</given-names></name><name><surname>Fung</surname> <given-names>C</given-names></name><name><surname>Beck</surname> <given-names>J</given-names></name><name><surname>Sankowski</surname> <given-names>R</given-names></name><name><surname>Prinz</surname> <given-names>M</given-names></name><name><surname>Schnell</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma</article-title><source>Nature Communications</source><volume>10</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41467-019-10493-6</pub-id><pub-id pub-id-type="pmid">31186414</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodges</surname> <given-names>ME</given-names></name><name><surname>Wickstead</surname> <given-names>B</given-names></name><name><surname>Gull</surname> <given-names>K</given-names></name><name><surname>Langdale</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The evolution of land plant cilia</article-title><source>New Phytologist</source><volume>195</volume><fpage>526</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8137.2012.04197.x</pub-id><pub-id pub-id-type="pmid">22691130</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname> <given-names>PM</given-names></name><name><surname>Monteggia</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MeCP2 as an activator of gene Expression<italic>Trends</italic></article-title><source>NeuroSci</source><volume>41</volume><fpage>72</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2017.11.005</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Bernardo</surname> <given-names>Ddi</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Network based elucidation of drug response: from modulators to targets</article-title><source>BMC Systems Biology</source><volume>7</volume><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.1186/1752-0509-7-139</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jassal</surname> <given-names>B</given-names></name><name><surname>Matthews</surname> <given-names>L</given-names></name><name><surname>Viteri</surname> <given-names>G</given-names></name><name><surname>Gong</surname> <given-names>C</given-names></name><name><surname>Lorente</surname> <given-names>P</given-names></name><name><surname>Fabregat</surname> <given-names>A</given-names></name><name><surname>Sidiropoulos</surname> <given-names>K</given-names></name><name><surname>Cook</surname> <given-names>J</given-names></name><name><surname>Gillespie</surname> <given-names>M</given-names></name><name><surname>Haw</surname> <given-names>R</given-names></name><name><surname>Loney</surname> <given-names>F</given-names></name><name><surname>May</surname> <given-names>B</given-names></name><name><surname>Milacic</surname> <given-names>M</given-names></name><name><surname>Rothfels</surname> <given-names>K</given-names></name><name><surname>Sevilla</surname> <given-names>C</given-names></name><name><surname>Shamovsky</surname> <given-names>V</given-names></name><name><surname>Shorser</surname> <given-names>S</given-names></name><name><surname>Varusai</surname> <given-names>T</given-names></name><name><surname>Weiser</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Stein</surname> <given-names>L</given-names></name><name><surname>Hermjakob</surname> <given-names>H</given-names></name><name><surname>D'Eustachio</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The reactome pathway knowledgebase</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D498</fpage><lpage>D503</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1031</pub-id><pub-id pub-id-type="pmid">31691815</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname> <given-names>KV</given-names></name><name><surname>Cseh</surname> <given-names>O</given-names></name><name><surname>Aman</surname> <given-names>A</given-names></name><name><surname>Weiss</surname> <given-names>S</given-names></name><name><surname>Luchman</surname> <given-names>HA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0189670</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0189670</pub-id><pub-id pub-id-type="pmid">29253028</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Protein function predictions based on the phylogenetic profile method</article-title><source>Critical Reviews in Biotechnology</source><volume>28</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1080/07388550802512633</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>X-R</given-names></name><name><surname>Chen</surname> <given-names>X-S</given-names></name><name><surname>Xiao</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MeCP2 deficiency in Neuroglia: new progress in the pathogenesis of rett syndrome</article-title><source>Frontiers in Molecular Neuroscience</source><volume>10</volume><elocation-id>316</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2017.00316</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname> <given-names>H-R</given-names></name><name><surname>Kim</surname> <given-names>Y-S</given-names></name><name><surname>Son</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Erythropoietin and carbamylated erythropoietin promote histone deacetylase 5 phosphorylation and nuclear export in rat hippocampal neurons</article-title><source>Biochemical and Biophysical Research Communications</source><volume>470</volume><fpage>220</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.01.039</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahanovitch</surname> <given-names>U</given-names></name><name><surname>Patterson</surname> <given-names>KC</given-names></name><name><surname>Hernandez</surname> <given-names>R</given-names></name><name><surname>Olsen</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Glial dysfunction in MeCP2 deficiency models: implications for rett syndrome</article-title><source>International Journal of Molecular Sciences</source><volume>20</volume><elocation-id>3813</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20153813</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalinin</surname> <given-names>S</given-names></name><name><surname>Polak</surname> <given-names>PE</given-names></name><name><surname>Lin</surname> <given-names>SX</given-names></name><name><surname>Braun</surname> <given-names>D</given-names></name><name><surname>Guizzetti</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Rubinstein</surname> <given-names>I</given-names></name><name><surname>Feinstein</surname> <given-names>DL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dimethyl fumarate regulates histone deacetylase expression in astrocytes</article-title><source>Journal of Neuroimmunology</source><volume>263</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2013.07.007</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname> <given-names>M</given-names></name><name><surname>Goto</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Research</source><volume>28</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmid">10592173</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasprzyk</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>BioMart: driving a paradigm change in biological data management</article-title><source>Database</source><volume>2011</volume><elocation-id>bar049</elocation-id><pub-id pub-id-type="doi">10.1093/database/bar049</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname> <given-names>WE</given-names></name><name><surname>Sprouse</surname> <given-names>J</given-names></name><name><surname>Rebowe</surname> <given-names>N</given-names></name><name><surname>Hanania</surname> <given-names>T</given-names></name><name><surname>Klamer</surname> <given-names>D</given-names></name><name><surname>Missling</surname> <given-names>CU</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>ANAVEX2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of rett syndrome</article-title><source>Pharmacology Biochemistry and Behavior</source><volume>187</volume><elocation-id>172796</elocation-id><pub-id pub-id-type="doi">10.1016/j.pbb.2019.172796</pub-id><pub-id pub-id-type="pmid">31704481</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khwaja</surname> <given-names>OS</given-names></name><name><surname>Ho</surname> <given-names>E</given-names></name><name><surname>Barnes</surname> <given-names>KV</given-names></name><name><surname>O'Leary</surname> <given-names>HM</given-names></name><name><surname>Pereira</surname> <given-names>LM</given-names></name><name><surname>Finkelstein</surname> <given-names>Y</given-names></name><name><surname>Nelson</surname> <given-names>CA</given-names></name><name><surname>Vogel-Farley</surname> <given-names>V</given-names></name><name><surname>DeGregorio</surname> <given-names>G</given-names></name><name><surname>Holm</surname> <given-names>IA</given-names></name><name><surname>Khatwa</surname> <given-names>U</given-names></name><name><surname>Kapur</surname> <given-names>K</given-names></name><name><surname>Alexander</surname> <given-names>ME</given-names></name><name><surname>Finnegan</surname> <given-names>DM</given-names></name><name><surname>Cantwell</surname> <given-names>NG</given-names></name><name><surname>Walco</surname> <given-names>AC</given-names></name><name><surname>Rappaport</surname> <given-names>L</given-names></name><name><surname>Gregas</surname> <given-names>M</given-names></name><name><surname>Fichorova</surname> <given-names>RN</given-names></name><name><surname>Shannon</surname> <given-names>MW</given-names></name><name><surname>Sur</surname> <given-names>M</given-names></name><name><surname>Kaufmann</surname> <given-names>WE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of rett syndrome</article-title><source>PNAS</source><volume>111</volume><fpage>4596</fpage><lpage>4601</lpage><pub-id pub-id-type="doi">10.1073/pnas.1311141111</pub-id><pub-id pub-id-type="pmid">24623853</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>Y</given-names></name><name><surname>Subramaniam</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Locally defined protein phylogenetic profiles reveal previously missed protein interactions and functional relationships, <italic>proteins struct</italic></article-title><source>Funct. Genet</source><volume>62</volume><fpage>1115</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1002/prot.20830</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname> <given-names>N</given-names></name><name><surname>MacDonald</surname> <given-names>JL</given-names></name><name><surname>Ye</surname> <given-names>J</given-names></name><name><surname>Molyneaux</surname> <given-names>BJ</given-names></name><name><surname>Azim</surname> <given-names>E</given-names></name><name><surname>Macklis</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reduction of aberrant NF-κB signalling ameliorates rett syndrome phenotypes in Mecp2-null mice</article-title><source>Nature Communications</source><volume>7</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/ncomms10520</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kline</surname> <given-names>DD</given-names></name><name><surname>Ogier</surname> <given-names>M</given-names></name><name><surname>Kunze</surname> <given-names>DL</given-names></name><name><surname>Katz</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice</article-title><source>Journal of Neuroscience</source><volume>30</volume><fpage>5303</fpage><lpage>5310</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5503-09.2010</pub-id><pub-id pub-id-type="pmid">20392952</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnaraj</surname> <given-names>R</given-names></name><name><surname>Ho</surname> <given-names>G</given-names></name><name><surname>Christodoulou</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RettBASE: rett syndrome database update</article-title><source>Human Mutation</source><volume>38</volume><fpage>922</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1002/humu.23263</pub-id><pub-id pub-id-type="pmid">28544139</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Calfa</surname> <given-names>G</given-names></name><name><surname>Larimore</surname> <given-names>J</given-names></name><name><surname>Pozzo-Miller</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Activity-dependent BDNF release and TRPC signaling is impaired in hippocampal neurons of Mecp2 mutant mice</article-title><source>PNAS</source><volume>109</volume><fpage>17087</fpage><lpage>17092</lpage><pub-id pub-id-type="doi">10.1073/pnas.1205271109</pub-id><pub-id pub-id-type="pmid">23027959</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liyanage</surname> <given-names>VR</given-names></name><name><surname>Rastegar</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rett syndrome and MeCP2</article-title><source>NeuroMolecular Medicine</source><volume>16</volume><fpage>231</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1007/s12017-014-8295-9</pub-id><pub-id pub-id-type="pmid">24615633</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomonaco</surname> <given-names>SL</given-names></name><name><surname>Finniss</surname> <given-names>S</given-names></name><name><surname>Xiang</surname> <given-names>C</given-names></name><name><surname>DeCarvalho</surname> <given-names>A</given-names></name><name><surname>Umansky</surname> <given-names>F</given-names></name><name><surname>Kalkanis</surname> <given-names>SN</given-names></name><name><surname>Mikkelsen</surname> <given-names>T</given-names></name><name><surname>Brodie</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The induction of autophagy by Î³-radiation contributes to the radioresistance of glioma stem cells</article-title><source>International Journal of Cancer</source><volume>125</volume><fpage>717</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1002/ijc.24402</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lopes</surname> <given-names>CT</given-names></name><name><surname>Franz</surname> <given-names>M</given-names></name><name><surname>Kazi</surname> <given-names>F</given-names></name><name><surname>Donaldson</surname> <given-names>SL</given-names></name><name><surname>Morris</surname> <given-names>Q</given-names></name><name><surname>Bader</surname> <given-names>GD</given-names></name><name><surname>Dopazo</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><source>Bioinformatics</source><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyst</surname> <given-names>MJ</given-names></name><name><surname>Ekiert</surname> <given-names>R</given-names></name><name><surname>Ebert</surname> <given-names>DH</given-names></name><name><surname>Merusi</surname> <given-names>C</given-names></name><name><surname>Nowak</surname> <given-names>J</given-names></name><name><surname>Selfridge</surname> <given-names>J</given-names></name><name><surname>Guy</surname> <given-names>J</given-names></name><name><surname>Kastan</surname> <given-names>NR</given-names></name><name><surname>Robinson</surname> <given-names>ND</given-names></name><name><surname>de Lima Alves</surname> <given-names>F</given-names></name><name><surname>Rappsilber</surname> <given-names>J</given-names></name><name><surname>Greenberg</surname> <given-names>ME</given-names></name><name><surname>Bird</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor</article-title><source>Nature Neuroscience</source><volume>16</volume><fpage>898</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1038/nn.3434</pub-id><pub-id pub-id-type="pmid">23770565</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maezawa</surname> <given-names>I</given-names></name><name><surname>Swanberg</surname> <given-names>S</given-names></name><name><surname>Harvey</surname> <given-names>D</given-names></name><name><surname>LaSalle</surname> <given-names>JM</given-names></name><name><surname>Jin</surname> <given-names>LW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions</article-title><source>Journal of Neuroscience</source><volume>29</volume><fpage>5051</fpage><lpage>5061</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0324-09.2009</pub-id><pub-id pub-id-type="pmid">19386901</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcotte</surname> <given-names>EM</given-names></name><name><surname>Xenarios</surname> <given-names>I</given-names></name><name><surname>van Der Bliek</surname> <given-names>AM</given-names></name><name><surname>Eisenberg</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Localizing proteins in the cell from their phylogenetic profiles</article-title><source>PNAS</source><volume>97</volume><fpage>12115</fpage><lpage>12120</lpage><pub-id pub-id-type="doi">10.1073/pnas.220399497</pub-id><pub-id pub-id-type="pmid">11035803</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merchant</surname> <given-names>SS</given-names></name><name><surname>Prochnik</surname> <given-names>SE</given-names></name><name><surname>Vallon</surname> <given-names>O</given-names></name><name><surname>Harris</surname> <given-names>EH</given-names></name><name><surname>Karpowicz</surname> <given-names>SJ</given-names></name><name><surname>Witman</surname> <given-names>GB</given-names></name><name><surname>Terry</surname> <given-names>A</given-names></name><name><surname>Salamov</surname> <given-names>A</given-names></name><name><surname>Fritz-Laylin</surname> <given-names>LK</given-names></name><name><surname>Maréchal-Drouard</surname> <given-names>L</given-names></name><name><surname>Marshall</surname> <given-names>WF</given-names></name><name><surname>Qu</surname> <given-names>LH</given-names></name><name><surname>Nelson</surname> <given-names>DR</given-names></name><name><surname>Sanderfoot</surname> <given-names>AA</given-names></name><name><surname>Spalding</surname> <given-names>MH</given-names></name><name><surname>Kapitonov</surname> <given-names>VV</given-names></name><name><surname>Ren</surname> <given-names>Q</given-names></name><name><surname>Ferris</surname> <given-names>P</given-names></name><name><surname>Lindquist</surname> <given-names>E</given-names></name><name><surname>Shapiro</surname> <given-names>H</given-names></name><name><surname>Lucas</surname> <given-names>SM</given-names></name><name><surname>Grimwood</surname> <given-names>J</given-names></name><name><surname>Schmutz</surname> <given-names>J</given-names></name><name><surname>Cardol</surname> <given-names>P</given-names></name><name><surname>Cerutti</surname> <given-names>H</given-names></name><name><surname>Chanfreau</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>CL</given-names></name><name><surname>Cognat</surname> <given-names>V</given-names></name><name><surname>Croft</surname> <given-names>MT</given-names></name><name><surname>Dent</surname> <given-names>R</given-names></name><name><surname>Dutcher</surname> <given-names>S</given-names></name><name><surname>Fernández</surname> <given-names>E</given-names></name><name><surname>Fukuzawa</surname> <given-names>H</given-names></name><name><surname>González-Ballester</surname> <given-names>D</given-names></name><name><surname>González-Halphen</surname> <given-names>D</given-names></name><name><surname>Hallmann</surname> <given-names>A</given-names></name><name><surname>Hanikenne</surname> <given-names>M</given-names></name><name><surname>Hippler</surname> <given-names>M</given-names></name><name><surname>Inwood</surname> <given-names>W</given-names></name><name><surname>Jabbari</surname> <given-names>K</given-names></name><name><surname>Kalanon</surname> <given-names>M</given-names></name><name><surname>Kuras</surname> <given-names>R</given-names></name><name><surname>Lefebvre</surname> <given-names>PA</given-names></name><name><surname>Lemaire</surname> <given-names>SD</given-names></name><name><surname>Lobanov</surname> <given-names>AV</given-names></name><name><surname>Lohr</surname> <given-names>M</given-names></name><name><surname>Manuell</surname> <given-names>A</given-names></name><name><surname>Meier</surname> <given-names>I</given-names></name><name><surname>Mets</surname> <given-names>L</given-names></name><name><surname>Mittag</surname> <given-names>M</given-names></name><name><surname>Mittelmeier</surname> <given-names>T</given-names></name><name><surname>Moroney</surname> <given-names>JV</given-names></name><name><surname>Moseley</surname> <given-names>J</given-names></name><name><surname>Napoli</surname> <given-names>C</given-names></name><name><surname>Nedelcu</surname> <given-names>AM</given-names></name><name><surname>Niyogi</surname> <given-names>K</given-names></name><name><surname>Novoselov</surname> <given-names>SV</given-names></name><name><surname>Paulsen</surname> <given-names>IT</given-names></name><name><surname>Pazour</surname> <given-names>G</given-names></name><name><surname>Purton</surname> <given-names>S</given-names></name><name><surname>Ral</surname> <given-names>JP</given-names></name><name><surname>Riaño-Pachón</surname> <given-names>DM</given-names></name><name><surname>Riekhof</surname> <given-names>W</given-names></name><name><surname>Rymarquis</surname> <given-names>L</given-names></name><name><surname>Schroda</surname> <given-names>M</given-names></name><name><surname>Stern</surname> <given-names>D</given-names></name><name><surname>Umen</surname> <given-names>J</given-names></name><name><surname>Willows</surname> <given-names>R</given-names></name><name><surname>Wilson</surname> <given-names>N</given-names></name><name><surname>Zimmer</surname> <given-names>SL</given-names></name><name><surname>Allmer</surname> <given-names>J</given-names></name><name><surname>Balk</surname> <given-names>J</given-names></name><name><surname>Bisova</surname> <given-names>K</given-names></name><name><surname>Chen</surname> <given-names>CJ</given-names></name><name><surname>Elias</surname> <given-names>M</given-names></name><name><surname>Gendler</surname> <given-names>K</given-names></name><name><surname>Hauser</surname> <given-names>C</given-names></name><name><surname>Lamb</surname> <given-names>MR</given-names></name><name><surname>Ledford</surname> <given-names>H</given-names></name><name><surname>Long</surname> <given-names>JC</given-names></name><name><surname>Minagawa</surname> <given-names>J</given-names></name><name><surname>Page</surname> <given-names>MD</given-names></name><name><surname>Pan</surname> <given-names>J</given-names></name><name><surname>Pootakham</surname> <given-names>W</given-names></name><name><surname>Roje</surname> <given-names>S</given-names></name><name><surname>Rose</surname> <given-names>A</given-names></name><name><surname>Stahlberg</surname> <given-names>E</given-names></name><name><surname>Terauchi</surname> <given-names>AM</given-names></name><name><surname>Yang</surname> <given-names>P</given-names></name><name><surname>Ball</surname> <given-names>S</given-names></name><name><surname>Bowler</surname> <given-names>C</given-names></name><name><surname>Dieckmann</surname> <given-names>CL</given-names></name><name><surname>Gladyshev</surname> <given-names>VN</given-names></name><name><surname>Green</surname> <given-names>P</given-names></name><name><surname>Jorgensen</surname> <given-names>R</given-names></name><name><surname>Mayfield</surname> <given-names>S</given-names></name><name><surname>Mueller-Roeber</surname> <given-names>B</given-names></name><name><surname>Rajamani</surname> <given-names>S</given-names></name><name><surname>Sayre</surname> <given-names>RT</given-names></name><name><surname>Brokstein</surname> <given-names>P</given-names></name><name><surname>Dubchak</surname> <given-names>I</given-names></name><name><surname>Goodstein</surname> <given-names>D</given-names></name><name><surname>Hornick</surname> <given-names>L</given-names></name><name><surname>Huang</surname> <given-names>YW</given-names></name><name><surname>Jhaveri</surname> <given-names>J</given-names></name><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Martínez</surname> <given-names>D</given-names></name><name><surname>Ngau</surname> <given-names>WC</given-names></name><name><surname>Otillar</surname> <given-names>B</given-names></name><name><surname>Poliakov</surname> <given-names>A</given-names></name><name><surname>Porter</surname> <given-names>A</given-names></name><name><surname>Szajkowski</surname> <given-names>L</given-names></name><name><surname>Werner</surname> <given-names>G</given-names></name><name><surname>Zhou</surname> <given-names>K</given-names></name><name><surname>Grigoriev</surname> <given-names>IV</given-names></name><name><surname>Rokhsar</surname> <given-names>DS</given-names></name><name><surname>Grossman</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Chlamydomonas genome reveals the evolution of key animal and plant functions</article-title><source>Science</source><volume>318</volume><fpage>245</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1126/science.1143609</pub-id><pub-id pub-id-type="pmid">17932292</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname> <given-names>JK</given-names></name><name><surname>Collins</surname> <given-names>BE</given-names></name><name><surname>Erickson</surname> <given-names>KR</given-names></name><name><surname>Dong</surname> <given-names>H</given-names></name><name><surname>Neul</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pharmacological read-through of R294X Mecp2 in a novel mouse model of rett syndrome</article-title><source>Human Molecular Genetics</source><volume>29</volume><fpage>2461</fpage><lpage>2470</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddaa102</pub-id><pub-id pub-id-type="pmid">32469049</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Mok</surname> <given-names>RS</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Sheikh</surname> <given-names>T</given-names></name><name><surname>Fernandes</surname> <given-names>I</given-names></name><name><surname>DeJong</surname> <given-names>L</given-names></name><name><surname>Hildebrandt</surname> <given-names>M</given-names></name><name><surname>Mufteev</surname> <given-names>M</given-names></name><name><surname>Rodrigues</surname> <given-names>D</given-names></name><name><surname>Wei</surname> <given-names>W</given-names></name><name><surname>Piekna</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Muotri</surname> <given-names>A</given-names></name><name><surname>Vincent</surname> <given-names>J</given-names></name><name><surname>Salter</surname> <given-names>M</given-names></name><name><surname>Ellis</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Wide phenotypic spectrum of human stem cell-derived excitatory neurons with rett syndrome-associated MECP2 mutations</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.07.12.189621</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montes Diaz</surname> <given-names>G</given-names></name><name><surname>Hupperts</surname> <given-names>R</given-names></name><name><surname>Fraussen</surname> <given-names>J</given-names></name><name><surname>Somers</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dimethyl fumarate treatment in multiple sclerosis: recent advances in clinical and immunological studies</article-title><source>Autoimmunity Reviews</source><volume>17</volume><fpage>1240</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2018.07.001</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname> <given-names>B</given-names></name><name><surname>Wong-Riley</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcriptional regulation of Brain-derived neurotrophic factor coding exon IX: role of nuclear respiratory factor 2</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>22583</fpage><lpage>22593</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.742304</pub-id><pub-id pub-id-type="pmid">27624937</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nan</surname> <given-names>X</given-names></name><name><surname>Ng</surname> <given-names>HH</given-names></name><name><surname>Johnson</surname> <given-names>CA</given-names></name><name><surname>Laherty</surname> <given-names>CD</given-names></name><name><surname>Turner</surname> <given-names>BM</given-names></name><name><surname>Eisenman</surname> <given-names>RN</given-names></name><name><surname>Bird</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex</article-title><source>Nature</source><volume>393</volume><fpage>386</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/30764</pub-id><pub-id pub-id-type="pmid">9620804</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname> <given-names>MR</given-names></name><name><surname>Tipney</surname> <given-names>H</given-names></name><name><surname>Painter</surname> <given-names>JL</given-names></name><name><surname>Shen</surname> <given-names>J</given-names></name><name><surname>Nicoletti</surname> <given-names>P</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Floratos</surname> <given-names>A</given-names></name><name><surname>Sham</surname> <given-names>PC</given-names></name><name><surname>Li</surname> <given-names>MJ</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Cardon</surname> <given-names>LR</given-names></name><name><surname>Whittaker</surname> <given-names>JC</given-names></name><name><surname>Sanseau</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The support of human genetic evidence for approved drug indications</article-title><source>Nature Genetics</source><volume>47</volume><fpage>856</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1038/ng.3314</pub-id><pub-id pub-id-type="pmid">26121088</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neul</surname> <given-names>JL</given-names></name><name><surname>Fang</surname> <given-names>P</given-names></name><name><surname>Barrish</surname> <given-names>J</given-names></name><name><surname>Lane</surname> <given-names>J</given-names></name><name><surname>Caeg</surname> <given-names>EB</given-names></name><name><surname>Smith</surname> <given-names>EO</given-names></name><name><surname>Zoghbi</surname> <given-names>H</given-names></name><name><surname>Percy</surname> <given-names>A</given-names></name><name><surname>Glaze</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Specific mutations in methyl-CpG-binding protein 2 confer different severity in rett syndrome</article-title><source>Neurology</source><volume>70</volume><fpage>1313</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000291011.54508.aa</pub-id><pub-id pub-id-type="pmid">18337588</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname> <given-names>NTT</given-names></name><name><surname>Vincens</surname> <given-names>P</given-names></name><name><surname>Roest Crollius</surname> <given-names>H</given-names></name><name><surname>Louis</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genomicus 2018: karyotype evolutionary trees and on-the-fly synteny computing</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>D816</fpage><lpage>D822</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1003</pub-id><pub-id pub-id-type="pmid">29087490</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Driscoll</surname> <given-names>CM</given-names></name><name><surname>Lima</surname> <given-names>MP</given-names></name><name><surname>Kaufmann</surname> <given-names>WE</given-names></name><name><surname>Bressler</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Methyl CpG binding protein 2 deficiency enhances expression of inflammatory cytokines by sustaining NF-κB signaling in myeloid derived cells</article-title><source>Journal of Neuroimmunology</source><volume>283</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2015.04.005</pub-id><pub-id pub-id-type="pmid">26004152</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname> <given-names>Y</given-names></name><name><surname>Takahashi</surname> <given-names>T</given-names></name><name><surname>Mitsumasu</surname> <given-names>C</given-names></name><name><surname>Kosai</surname> <given-names>K</given-names></name><name><surname>Tanaka</surname> <given-names>E</given-names></name><name><surname>Matsuishi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of rett syndrome</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e35354</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035354</pub-id><pub-id pub-id-type="pmid">22532851</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Oxford Academic</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Open targets platform: new developments and updates two years on | nucleic acids research |</article-title><ext-link ext-link-type="uri" xlink:href="https://academic.oup.com/nar/article/47/D1/D1056/5193331">https://academic.oup.com/nar/article/47/D1/D1056/5193331</ext-link><date-in-citation iso-8601-date="2019-01-08">January 8, 2019</date-in-citation></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliarini</surname> <given-names>DJ</given-names></name><name><surname>Calvo</surname> <given-names>SE</given-names></name><name><surname>Chang</surname> <given-names>B</given-names></name><name><surname>Sheth</surname> <given-names>SA</given-names></name><name><surname>Vafai</surname> <given-names>SB</given-names></name><name><surname>Ong</surname> <given-names>SE</given-names></name><name><surname>Walford</surname> <given-names>GA</given-names></name><name><surname>Sugiana</surname> <given-names>C</given-names></name><name><surname>Boneh</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>WK</given-names></name><name><surname>Hill</surname> <given-names>DE</given-names></name><name><surname>Vidal</surname> <given-names>M</given-names></name><name><surname>Evans</surname> <given-names>JG</given-names></name><name><surname>Thorburn</surname> <given-names>DR</given-names></name><name><surname>Carr</surname> <given-names>SA</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A mitochondrial protein compendium elucidates complex I disease biology</article-title><source>Cell</source><volume>134</volume><fpage>112</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.06.016</pub-id><pub-id pub-id-type="pmid">18614015</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>MJ</given-names></name><name><surname>Aja</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Degano</surname> <given-names>AL</given-names></name><name><surname>Penati</surname> <given-names>J</given-names></name><name><surname>Zhuo</surname> <given-names>J</given-names></name><name><surname>Roe</surname> <given-names>CR</given-names></name><name><surname>Ronnett</surname> <given-names>GV</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-Null mice</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e109527</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0109527</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>NS</given-names></name><name><surname>Nandra</surname> <given-names>KK</given-names></name><name><surname>Brines</surname> <given-names>M</given-names></name><name><surname>Collino</surname> <given-names>M</given-names></name><name><surname>Wong</surname> <given-names>WF</given-names></name><name><surname>Kapoor</surname> <given-names>A</given-names></name><name><surname>Benetti</surname> <given-names>E</given-names></name><name><surname>Goh</surname> <given-names>FY</given-names></name><name><surname>Fantozzi</surname> <given-names>R</given-names></name><name><surname>Cerami</surname> <given-names>A</given-names></name><name><surname>Thiemermann</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock</article-title><source>Molecular Medicine</source><volume>17</volume><fpage>883</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.2119/molmed.2011.00053</pub-id><pub-id pub-id-type="pmid">21607291</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrini</surname> <given-names>M</given-names></name><name><surname>Marcotte</surname> <given-names>EM</given-names></name><name><surname>Thompson</surname> <given-names>MJ</given-names></name><name><surname>Eisenberg</surname> <given-names>D</given-names></name><name><surname>Yeates</surname> <given-names>TO</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Assigning protein functions by comparative genome analysis: protein phylogenetic profiles</article-title><source>PNAS</source><volume>96</volume><fpage>4285</fpage><lpage>4288</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.8.4285</pub-id><pub-id pub-id-type="pmid">10200254</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname> <given-names>N</given-names></name><name><surname>Fagiolini</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MeCP2: an epigenetic regulator of critical periods</article-title><source>Current Opinion in Neurobiology</source><volume>59</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2019.04.004</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przanowski</surname> <given-names>P</given-names></name><name><surname>Wasko</surname> <given-names>U</given-names></name><name><surname>Zheng</surname> <given-names>Z</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Sherman</surname> <given-names>R</given-names></name><name><surname>Zhu</surname> <given-names>LJ</given-names></name><name><surname>McConnell</surname> <given-names>MJ</given-names></name><name><surname>Tushir-Singh</surname> <given-names>J</given-names></name><name><surname>Green</surname> <given-names>MR</given-names></name><name><surname>Bhatnagar</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pharmacological reactivation of inactive X-linked <italic>Mecp2</italic> in cerebral cortical neurons of living mice</article-title><source>PNAS</source><volume>115</volume><fpage>7991</fpage><lpage>7996</lpage><pub-id pub-id-type="doi">10.1073/pnas.1803792115</pub-id><pub-id pub-id-type="pmid">30012595</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pushpakom</surname> <given-names>S</given-names></name><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Eyers</surname> <given-names>PA</given-names></name><name><surname>Escott</surname> <given-names>KJ</given-names></name><name><surname>Hopper</surname> <given-names>S</given-names></name><name><surname>Wells</surname> <given-names>A</given-names></name><name><surname>Doig</surname> <given-names>A</given-names></name><name><surname>Guilliams</surname> <given-names>T</given-names></name><name><surname>Latimer</surname> <given-names>J</given-names></name><name><surname>McNamee</surname> <given-names>C</given-names></name><name><surname>Norris</surname> <given-names>A</given-names></name><name><surname>Sanseau</surname> <given-names>P</given-names></name><name><surname>Cavalla</surname> <given-names>D</given-names></name><name><surname>Pirmohamed</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Drug repurposing: progress, challenges and recommendations</article-title><source>Nature Reviews Drug Discovery</source><volume>18</volume><fpage>41</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.168</pub-id><pub-id pub-id-type="pmid">30310233</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragione</surname> <given-names>FD</given-names></name><name><surname>Vacca</surname> <given-names>M</given-names></name><name><surname>Fioriniello</surname> <given-names>S</given-names></name><name><surname>Pepe</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MECP2, a multi-talented modulator of chromatin architecture | briefings in functional genomics | oxford academic, <italic>br</italic></article-title><source>Funct Genomics</source><volume>15</volume><fpage>420</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1093/bfgp/elw023</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramocki</surname> <given-names>MB</given-names></name><name><surname>Peters</surname> <given-names>SU</given-names></name><name><surname>Tavyev</surname> <given-names>YJ</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Carvalho</surname> <given-names>CM</given-names></name><name><surname>Schaaf</surname> <given-names>CP</given-names></name><name><surname>Richman</surname> <given-names>R</given-names></name><name><surname>Fang</surname> <given-names>P</given-names></name><name><surname>Glaze</surname> <given-names>DG</given-names></name><name><surname>Lupski</surname> <given-names>JR</given-names></name><name><surname>Zoghbi</surname> <given-names>HY</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome</article-title><source>Annals of Neurology</source><volume>66</volume><fpage>771</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1002/ana.21715</pub-id><pub-id pub-id-type="pmid">20035514</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname> <given-names>SS</given-names></name><name><surname>Huntley</surname> <given-names>MH</given-names></name><name><surname>Durand</surname> <given-names>NC</given-names></name><name><surname>Stamenova</surname> <given-names>EK</given-names></name><name><surname>Bochkov</surname> <given-names>ID</given-names></name><name><surname>Robinson</surname> <given-names>JT</given-names></name><name><surname>Sanborn</surname> <given-names>AL</given-names></name><name><surname>Machol</surname> <given-names>I</given-names></name><name><surname>Omer</surname> <given-names>AD</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Aiden</surname> <given-names>EL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A 3D map of the human genome at Kilobase resolution reveals principles of chromatin looping</article-title><source>Cell</source><volume>159</volume><fpage>1665</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.11.021</pub-id><pub-id pub-id-type="pmid">25497547</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rey</surname> <given-names>F</given-names></name><name><surname>Balsari</surname> <given-names>A</given-names></name><name><surname>Giallongo</surname> <given-names>T</given-names></name><name><surname>Ottolenghi</surname> <given-names>S</given-names></name><name><surname>Di Giulio</surname> <given-names>AM</given-names></name><name><surname>Samaja</surname> <given-names>M</given-names></name><name><surname>Carelli</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Erythropoietin as a neuroprotective molecule: an overview of its therapeutic potential in neurodegenerative diseases</article-title><source>ASN Neuro</source><volume>11</volume><elocation-id>175909141987142</elocation-id><pub-id pub-id-type="doi">10.1177/1759091419871420</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruepp</surname> <given-names>A</given-names></name><name><surname>Brauner</surname> <given-names>B</given-names></name><name><surname>Dunger-Kaltenbach</surname> <given-names>I</given-names></name><name><surname>Frishman</surname> <given-names>G</given-names></name><name><surname>Montrone</surname> <given-names>C</given-names></name><name><surname>Stransky</surname> <given-names>M</given-names></name><name><surname>Waegele</surname> <given-names>B</given-names></name><name><surname>Schmidt</surname> <given-names>T</given-names></name><name><surname>Doudieu</surname> <given-names>ON</given-names></name><name><surname>Stümpflen</surname> <given-names>V</given-names></name><name><surname>Mewes</surname> <given-names>HW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CORUM: the comprehensive resource of mammalian protein complexes</article-title><source>Nucleic Acids Research</source><volume>36</volume><fpage>D646</fpage><lpage>D650</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm936</pub-id><pub-id pub-id-type="pmid">17965090</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname> <given-names>S</given-names></name><name><surname>Agarwala</surname> <given-names>SD</given-names></name><name><surname>Mumbach</surname> <given-names>MR</given-names></name><name><surname>Jovanovic</surname> <given-names>M</given-names></name><name><surname>Mertins</surname> <given-names>P</given-names></name><name><surname>Shishkin</surname> <given-names>A</given-names></name><name><surname>Tabach</surname> <given-names>Y</given-names></name><name><surname>Mikkelsen</surname> <given-names>TS</given-names></name><name><surname>Satija</surname> <given-names>R</given-names></name><name><surname>Ruvkun</surname> <given-names>G</given-names></name><name><surname>Carr</surname> <given-names>SA</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Fink</surname> <given-names>GR</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High-resolution mapping reveals a conserved, widespread, dynamic mRNA methylation program in yeast meiosis</article-title><source>Cell</source><volume>155</volume><fpage>1409</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.10.047</pub-id><pub-id pub-id-type="pmid">24269006</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherill-Rofe</surname> <given-names>D</given-names></name><name><surname>Rahat</surname> <given-names>D</given-names></name><name><surname>Findlay</surname> <given-names>S</given-names></name><name><surname>Mellul</surname> <given-names>A</given-names></name><name><surname>Guberman</surname> <given-names>I</given-names></name><name><surname>Braun</surname> <given-names>M</given-names></name><name><surname>Bloch</surname> <given-names>I</given-names></name><name><surname>Lalezari</surname> <given-names>A</given-names></name><name><surname>Samiei</surname> <given-names>A</given-names></name><name><surname>Sadreyev</surname> <given-names>R</given-names></name><name><surname>Goldberg</surname> <given-names>M</given-names></name><name><surname>Orthwein</surname> <given-names>A</given-names></name><name><surname>Zick</surname> <given-names>A</given-names></name><name><surname>Tabach</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mapping global and local coevolution across 600 species to identify novel homologous recombination repair genes</article-title><source>Genome Research</source><volume>29</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1101/gr.241414.118</pub-id><pub-id pub-id-type="pmid">30718334</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shovlin</surname> <given-names>S</given-names></name><name><surname>Tropea</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transcriptome level analysis in rett syndrome using human samples from different tissues<italic>Orphanet J</italic></article-title><source>Rare Diseases</source><volume>13</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.1186/s13023-018-0857-8</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname> <given-names>S</given-names></name><name><surname>Tekwani</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation</article-title><source>Frontiers in Pharmacology</source><volume>11</volume><elocation-id>537</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2020.00537</pub-id><pub-id pub-id-type="pmid">32390854</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname> <given-names>JW</given-names></name><name><surname>Fleischman</surname> <given-names>A</given-names></name><name><surname>Al-Fayoumi</surname> <given-names>S</given-names></name><name><surname>Mascarenhas</surname> <given-names>JO</given-names></name><name><surname>Yu</surname> <given-names>Q</given-names></name><name><surname>Agarwal</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy</article-title><source>Oncotarget</source><volume>9</volume><fpage>33416</fpage><lpage>33439</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.26058</pub-id><pub-id pub-id-type="pmid">30279971</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Zhao</surname> <given-names>A</given-names></name><name><surname>Shi</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Refined phylogenetic profiles method for predicting protein-protein interactions</article-title><source>Bioinformatics</source><volume>21</volume><fpage>3409</fpage><lpage>3415</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bti532</pub-id><pub-id pub-id-type="pmid">15947018</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname> <given-names>D</given-names></name><name><surname>Gable</surname> <given-names>AL</given-names></name><name><surname>Lyon</surname> <given-names>D</given-names></name><name><surname>Junge</surname> <given-names>A</given-names></name><name><surname>Wyder</surname> <given-names>S</given-names></name><name><surname>Huerta-Cepas</surname> <given-names>J</given-names></name><name><surname>Simonovic</surname> <given-names>M</given-names></name><name><surname>Doncheva</surname> <given-names>NT</given-names></name><name><surname>Morris</surname> <given-names>JH</given-names></name><name><surname>Bork</surname> <given-names>P</given-names></name><name><surname>Jensen</surname> <given-names>LJ</given-names></name><name><surname>Mering</surname> <given-names>CV</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id><pub-id pub-id-type="pmid">30476243</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabach</surname> <given-names>Y</given-names></name><name><surname>Golan</surname> <given-names>T</given-names></name><name><surname>Hernández-Hernández</surname> <given-names>A</given-names></name><name><surname>Messer</surname> <given-names>AR</given-names></name><name><surname>Fukuda</surname> <given-names>T</given-names></name><name><surname>Kouznetsova</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>JG</given-names></name><name><surname>Lilienthal</surname> <given-names>I</given-names></name><name><surname>Levy</surname> <given-names>C</given-names></name><name><surname>Ruvkun</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Human disease locus discovery and mapping to molecular pathways through phylogenetic profiling</article-title><source>Molecular Systems Biology</source><volume>9</volume><elocation-id>692</elocation-id><pub-id pub-id-type="doi">10.1038/msb.2013.50</pub-id><pub-id pub-id-type="pmid">24084807</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabach</surname> <given-names>Y</given-names></name><name><surname>Billi</surname> <given-names>AC</given-names></name><name><surname>Hayes</surname> <given-names>GD</given-names></name><name><surname>Newman</surname> <given-names>MA</given-names></name><name><surname>Zuk</surname> <given-names>O</given-names></name><name><surname>Gabel</surname> <given-names>H</given-names></name><name><surname>Kamath</surname> <given-names>R</given-names></name><name><surname>Yacoby</surname> <given-names>K</given-names></name><name><surname>Chapman</surname> <given-names>B</given-names></name><name><surname>Garcia</surname> <given-names>SM</given-names></name><name><surname>Borowsky</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>JK</given-names></name><name><surname>Ruvkun</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Identification of small RNA pathway genes using patterns of phylogenetic conservation and divergence</article-title><source>Nature</source><volume>493</volume><fpage>694</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1038/nature11779</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timmerman</surname> <given-names>R</given-names></name><name><surname>Burm</surname> <given-names>SM</given-names></name><name><surname>Bajramovic</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An overview of in vitro methods to study microglia</article-title><source>Frontiers in Cellular Neuroscience</source><volume>12</volume><elocation-id>242</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2018.00242</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torkildsen</surname> <given-names>Ø</given-names></name><name><surname>Myhr</surname> <given-names>KM</given-names></name><name><surname>Bø</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Disease‐modifying treatments for multiple sclerosis – a review of approved medications</article-title><source>European Journal of Neurology</source><volume>23</volume><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/ene.12883</pub-id><pub-id pub-id-type="pmid">26563094</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsaban</surname> <given-names>T</given-names></name><name><surname>Stupp</surname> <given-names>D</given-names></name><name><surname>Sherill-Rofe</surname> <given-names>D</given-names></name><name><surname>Bloch</surname> <given-names>I</given-names></name><name><surname>Sharon</surname> <given-names>E</given-names></name><name><surname>Schueler-Furman</surname> <given-names>O</given-names></name><name><surname>Wiener</surname> <given-names>R</given-names></name><name><surname>Tabach</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CladeOScope: functional interactions through the prism of clade-wise co-evolution</article-title><source>NAR Genomics and Bioinformatics</source><volume>3</volume><elocation-id>lqab024</elocation-id><pub-id pub-id-type="doi">10.1093/nargab/lqab024</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsilioni</surname> <given-names>I</given-names></name><name><surname>Pantazopoulos</surname> <given-names>H</given-names></name><name><surname>Conti</surname> <given-names>P</given-names></name><name><surname>Leeman</surname> <given-names>SE</given-names></name><name><surname>Theoharides</surname> <given-names>TC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder</article-title><source>PNAS</source><volume>117</volume><fpage>16475</fpage><lpage>16480</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004666117</pub-id><pub-id pub-id-type="pmid">32601180</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Unterman</surname> <given-names>I</given-names></name><name><surname>Berman</surname> <given-names>BP</given-names></name><name><surname>Tabach</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>MECP2_phylogeny</data-title><source>Software Heritage</source><version designator="swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad">swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad</version><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:e2c60f2c5038244f7192b1070c80c10bad4daeb0;origin=https://github.com/GuIrene/MECP2_phylogeny;visit=swh:1:snp:0c28d2131db499777078eb129237064f9b0c9be0;anchor=swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad">https://archive.softwareheritage.org/swh:1:dir:e2c60f2c5038244f7192b1070c80c10bad4daeb0;origin=https://github.com/GuIrene/MECP2_phylogeny;visit=swh:1:snp:0c28d2131db499777078eb129237064f9b0c9be0;anchor=swh:1:rev:14063b44a40688a8024a06347b63cfdac74b96ad</ext-link></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vashi</surname> <given-names>N</given-names></name><name><surname>Justice</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Treating rett syndrome: from mouse models to human therapies</article-title><source>Mammalian Genome</source><volume>30</volume><fpage>90</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/s00335-019-09793-5</pub-id><pub-id pub-id-type="pmid">30820643</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Kuang</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Choudhary</surname> <given-names>MNK</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Hu</surname> <given-names>M</given-names></name><name><surname>Hardison</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Yue</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The 3D genome browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>151</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1519-9</pub-id><pub-id pub-id-type="pmid">30286773</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Chen</surname> <given-names>C</given-names></name><name><surname>Ding</surname> <given-names>L</given-names></name><name><surname>Mo</surname> <given-names>M</given-names></name><name><surname>Zou</surname> <given-names>J</given-names></name><name><surname>Lu</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Dai</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>P</given-names></name><name><surname>Lu</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Wnt1 promotes EAAT2 expression and mediates the protective effects of astrocytes on dopaminergic cells in Parkinson’s Disease</article-title><source>Neural Plasticity</source><volume>2019</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2019/1247276</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Kozikowski</surname> <given-names>AP</given-names></name><name><surname>Pozzo-Miller</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for rett syndrome</article-title><source>Frontiers in Cellular Neuroscience</source><volume>8</volume><elocation-id>68</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2014.00068</pub-id><pub-id pub-id-type="pmid">24639629</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>X</given-names></name><name><surname>Stoyanova</surname> <given-names>EI</given-names></name><name><surname>Lemiesz</surname> <given-names>AE</given-names></name><name><surname>Xing</surname> <given-names>J</given-names></name><name><surname>Mash</surname> <given-names>DC</given-names></name><name><surname>Heintz</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Species and cell-type properties of classically defined human and rodent neurons and Glia</article-title><source>eLife</source><volume>7</volume><elocation-id>e37551</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.37551</pub-id><pub-id pub-id-type="pmid">30320555</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasui</surname> <given-names>DH</given-names></name><name><surname>Peddada</surname> <given-names>S</given-names></name><name><surname>Bieda</surname> <given-names>MC</given-names></name><name><surname>Vallero</surname> <given-names>RO</given-names></name><name><surname>Hogart</surname> <given-names>A</given-names></name><name><surname>Nagarajan</surname> <given-names>RP</given-names></name><name><surname>Thatcher</surname> <given-names>KN</given-names></name><name><surname>Farnham</surname> <given-names>PJ</given-names></name><name><surname>Lasalle</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes</article-title><source>PNAS</source><volume>104</volume><fpage>19416</fpage><lpage>19421</lpage><pub-id pub-id-type="doi">10.1073/pnas.0707442104</pub-id><pub-id pub-id-type="pmid">18042715</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname> <given-names>A</given-names></name><name><surname>Wei</surname> <given-names>Z</given-names></name><name><surname>Rabinovsky</surname> <given-names>R</given-names></name><name><surname>Jun</surname> <given-names>HJ</given-names></name><name><surname>El Fatimy</surname> <given-names>R</given-names></name><name><surname>Deforzh</surname> <given-names>E</given-names></name><name><surname>Arora</surname> <given-names>R</given-names></name><name><surname>Yao</surname> <given-names>Y</given-names></name><name><surname>Yao</surname> <given-names>S</given-names></name><name><surname>Yan</surname> <given-names>W</given-names></name><name><surname>Uhlmann</surname> <given-names>EJ</given-names></name><name><surname>Charest</surname> <given-names>A</given-names></name><name><surname>You</surname> <given-names>Y</given-names></name><name><surname>Krichevsky</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Glioblastoma-Derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism</article-title><source>iScience</source><volume>23</volume><elocation-id>101420</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2020.101420</pub-id><pub-id pub-id-type="pmid">32795915</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>D</given-names></name><name><surname>Mokhtari</surname> <given-names>R</given-names></name><name><surname>Pedrosa</surname> <given-names>E</given-names></name><name><surname>Birnbaum</surname> <given-names>R</given-names></name><name><surname>Zheng</surname> <given-names>D</given-names></name><name><surname>Lachman</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptome analysis of microglia in a mouse model of rett syndrome: differential expression of genes associated with microglia/macrophage activation and cellular stress</article-title><source>Molecular Autism</source><volume>8</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1186/s13229-017-0134-z</pub-id><pub-id pub-id-type="pmid">28367307</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67085.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Perry</surname><given-names>George H</given-names></name><role>Reviewing Editor</role><aff><institution>Pennsylvania State University</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.02.14.431162">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.02.14.431162v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript will interest scientists who are aiming to leverage concepts and tools of evolutionary biology to identify novel gene targets, in this case towards much-needed therapeutic interventions for Rett syndrome. The follow up experiments presented in the paper are detailed, well thought out, and help establish the potential of the identified drugs in alleviating molecular signatures in in vitro disease models.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by George Perry as the Senior and Reviewing Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The manuscript has potential but requires major revisions for further consideration by <italic>eLife</italic>. In consultation, the editor and reviewers considered the level of revision to be possible, but we emphasize that we have high expectations, expecting at least the major comments made by each reviewer (below) to be robustly addressed. These essential revisions include improving the comprehensiveness of the comparative genomics pipeline and the need for more explicit validation experiments.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>On line 367 – The differential mechanisms of restoration are interesting in the face of MeCP2s broad genomic role. While this is more of a future direction, could these treatments have a combinatorial beneficial effect? The in-vivo experiments that the authors are conducting should be very interesting. I wonder if all 33 identified genes could be screened for their toxicity/efficacy in these KD cells. The chosen 3 candidate proteins are all from the same evolutionarily conserved chromosomal cluster yet have meaningfully different cell specific mechanisms of RTT amelioration. Perhaps the other 33 identified genes with actionable druggable targets might have even more diverse mechanisms.</p><p>On line 51 there is a small typo, intro -&gt; into.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Addressing/answering the following comments would help provide supporting evidence for the comparative evolutionary pipeline used by the authors:</p><p>a. Can the authors elaborate on their NPP methodology and how did they avoid the false positives?</p><p>b. Is the functional nature of genes different between E200 and M200?</p><p>c. Is the overlap of 10 genes between E200 and M200 statistically significant, given that overlapping input data was used? Is it higher or lower than expected?</p><p>d. Among the 390 genes, how many well established functional and biophysical partners of MECP2 were identified? What positive controls did the authors use to validate the robustness of their comparative genomic pipeline?</p><p>e. HDACs appear to be highly connected functional and biophysical partners of MECP2. Yet the authors do not seem to have identified any of them. Can the authors speculate on the reasons behind that?</p><p>f. How many novel MECP2 partners (without any previously known links) do the authors identify?</p><p>g. Some of the partners identified by the authors have functional association in Stringdb. Can the authors perform an enrichment analysis, with randomized controls, to demonstrate whether this functional enrichment is significantly more than expected? It will be an important validation for the authors PP approach.</p><p>2. The authors detect that 33 out of the 390 genes are druggable targets. Is that higher/lower than expected?</p><p>3. The authors show a series of sophisticated experiments to demonstrate the impact of the three drugs. The following clarifications will help strengthen the importance of the evolutionary pipeline to identify these drugs:</p><p>a. Are any of the previously known MECP2 functional partners targeted by EPO, DMF and Pacritinib in DGIdb and Open Targets? For example, a quick literature survey shows that all three molecules have direct or indirect effects on HDAC activity, which are functional and biophysical interaction partners of MECP2.</p><p>b. If the authors were to use known functional partners of MECP2 from Stringdb, PDB, or biogrid and check for their druggability in DGIdb and Open Targets, will the authors identify EPO, DMF and Pacritinib? If not, it proves that the comparative genomic pipeline was critical for identification of these drugs. If yes, it shows that the authors didn't need the pipeline. Or perhaps the authors mean to demonstrate that EPOR, KEAP1 and IRAK work upstream of HDACs and are therefore contributing to a better understanding of the mechanism of action of MECP2. If so, the authors do not have enough text, analysis or experiments to demonstrate that.</p><p>c. Can the authors perform silencing or knockdown experiment to demonstrate that the effects of the three drugs are mediated through EPOR, KEAP1 and IRAK and not through other targets?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67085.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>On line 367 – The differential mechanisms of restoration are interesting in the face of MeCP2s broad genomic role. While this is more of a future direction, could these treatments have a combinatorial beneficial effect? The in-vivo experiments that the authors are conducting should be very interesting. I wonder if all 33 identified genes could be screened for their toxicity/efficacy in these KD cells. The chosen 3 candidate proteins are all from the same evolutionarily conserved chromosomal cluster yet have meaningfully different cell specific mechanisms of RTT amelioration. Perhaps the other 33 identified genes with actionable druggable targets might have even more diverse mechanisms.</p></disp-quote><p>We tested the combinatorial effect of EPO with DMF on BDNF secretion, since these two both had an individual effect on this phenotype and Pacritinib did not (new Figure 6C). There may be an additive effect to EPO+DMF, compared to EPO or DMF alone, though we did not see a substantial synergistic effect. While the points you make are largely beyond the scope of this initial study, we did incorporate some of them in the improvements to our Discussion section discussing future directions (lines 420-423, 483).</p><p>We note that only 2 of the 3 candidate proteins are from the same chromosomal cluster (EPOR and KEAP1), while IRAK1 is from a conserved cluster with MECP2. We have modified the text on lines 202-204 to make this clearer.</p><disp-quote content-type="editor-comment"><p>On line 51 there is a small typo, intro → into.</p></disp-quote><p>Fixed.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Addressing/answering the following comments would help provide supporting evidence for the comparative evolutionary pipeline used by the authors:</p><p>a. Can the authors elaborate on their NPP methodology and how did they avoid the false positives?</p></disp-quote><p>We described our two new methodology and benchmarking studies in the new Introduction on lines 104-109. Bloch et al. 2020 explicitly deals with the specificity issue using control datasets from the CORUM and KEGG databases. We have found that the most important factor in reducing false positives is our incorporation of within-clade normalization (discussed in Bloch 2020). In addition to our standard approach, we tried to additionally limit false positives by selecting candidates that were top-ranked in both the mammalian and eukaryotic lists, and that clustered within an evolutionarily conserved and topologically organized chromosomal domain.</p><disp-quote content-type="editor-comment"><p>b. Is the functional nature of genes different between E200 and M200?</p></disp-quote><p>We have done a new analysis of Gene Ontology and other functional annotations using STRING (now added as supplementary file 2). The E200 list is enriched in a number of different functional categories, with some of the most significant related to innate immunity and the immune response. These included MHC Class II receptor activity and peptidoglycan receptor activity. Consistent with this, autoimmunity annotations such as Asthma, Allograft rejection, and Type I diabetes are highly enriched in the KEGG network. In contrast, the M200 list has almost no functional enrichment, except for the general “Disease” category within Uniprot annotated keywords. This indicates that the two lists might be revealing fundamentally different relationships to MECP2, and makes the 10 overlapping genes especially interesting. We have added a description of this to the Results section in lines 152-159.</p><disp-quote content-type="editor-comment"><p>c. Is the overlap of 10 genes between E200 and M200 statistically significant, given that overlapping input data was used? Is it higher or lower than expected?</p></disp-quote><p>It is statistically significant if you consider the two lists independent (p&lt;3.2E-4 by the hypergeometric test), but as you point out the phylogenetic correlation in Eukaryotes can be affected by the correlation within the mammalian clade. We do not know a way to factor this out from the significance estimate, so we have just edited the description in the text to reflect this fact (lines 160-165).</p><disp-quote content-type="editor-comment"><p>d. Among the 390 genes, how many well established functional and biophysical partners of MECP2 were identified? What positive controls did the authors use to validate the robustness of their comparative genomic pipeline?</p></disp-quote><p>In the original manuscript, we relied on the fact that the 10 proteins in the E200/M200 intersection list included the well-established MECP2-interacting protein IRAK1. Given that evidence, and the fact that we have used this pipeline before and validated it extensively (Bloch et al., 2020; Tsaban et al., 2021), this gave us enough confidence to proceed to functional drug follow-up. However, based on your feedback we have now performed new comparisons to STRING to give a more comprehensive analysis for MECP2. See our response to question 1g, below.</p><disp-quote content-type="editor-comment"><p>e. HDACs appear to be highly connected functional and biophysical partners of MECP2. Yet the authors do not seem to have identified any of them. Can the authors speculate on the reasons behind that?</p></disp-quote><p>First, we investigated only the very most strongly linked of our PP lists, which would necessarily leave out some true interactions. However, we have gone back to our full original lists and found that the relevant HDACs have quite low PP similarity scores to MECP2 in general. We have plotted the phylogenetic profiles for MECP and the two major classes of HDACs in <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>, showing significant differences. MECP2 is distinguished by a relative loss among a large group of vertebrates, and stronger conservation among mammals. Class I HDACS 1/2/3/8 clustered together and were much better conserved in ancient branches. Class II HDACS 4/5/6/7/9/10 clustered together and were characterized by loss within a sub-branch of fungi and all non-fungi single-cell eukaryotes (“other organisms”). While it is hard to interpret these differences at more ancient time points, the split within the non-mammalian vertebrates may be important in understanding the divergence between MECP2 and HDACs. While we did not add this more in depth analysis of HDAC evolutionary conservation, we have added new text describing the HDAC role in MECP2 function and RTT in our Introduction on lines 72-80 and their potential role as a mediator of our drug candidates in the Discussion on lines 462-479.</p><fig id="sa2fig1"><label>Author response image 1.</label><caption><title>Normalized phylogenetic profiles of MECP2 and HDAC proteins.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-resp-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>f. How many novel MECP2 partners (without any previously known links) do the authors identify?</p></disp-quote><p>As shown in Figure 1—figure supplement 1D), there are 1,398 known interactions with MECP2 in the String-db categories “text-mining”, “co-expression”, and “experimental”. 366 of 390 genes in out E200+M200 list were not among these genes, indicating that large majority of our genes are novel relationships. We have added text describing this on lines 168-171.</p><disp-quote content-type="editor-comment"><p>g. Some of the partners identified by the authors have functional association in Stringdb. Can the authors perform an enrichment analysis, with randomized controls, to demonstrate whether this functional enrichment is significantly more than expected? It will be an important validation for the authors PP approach.</p></disp-quote><p>As described in response to your question 1f, only 24 of 390 genes in our E200+M200 gene lists (6.2%) had Stringdb associations with MECP2. Given that 1,398 (7.3%) of 19,257 total genes in Stringdb are associated with MECP2, this is compatible with random chance. However, in the 10 high priority genes included in both the M200 and E200 groups, 3 overlapped Stringdb (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>). The chance of observing 3 or more overlaps is 0.03 by the hypergeometric test. While this is not a high degree of overlap, it does help to establish the validity of our approach, along with our previous benchmarking of our pipeline using the CORUM, REACTOME, and KEGG databases (Bloch et al., 2020; Tsaban et al., 2021). These recent benchmarking studies are now described in lines 104-109. We also analyzed the 390 gene list using GeneAnalytics, and they were most enriched with genes expressed in the brain compared to all other tissues (see Figure 1—figure supplement 1C ).</p><fig id="sa2fig2"><label>Author response image 2.</label><caption><title>Overlap between the E200 and M200 intersection set (PP) and all STRING MECP2 interactions.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67085-resp-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>2. The authors detect that 33 out of the 390 genes are druggable targets. Is that higher/lower than expected?</p></disp-quote><p>We performed random sampling of 390 genes from our PP input gene list. This resulted in an average of 39.9 druggable genes (std 6.0). Thus our gene lists was not significantly either enriched or depleted in druggable genes. This does not seem surprising to us, given that druggability depends on priorities of past research efforts and chemical properties of the gene product, rather than anything having to do with evolutionary links. We have added a sentence describing this to the Results section (line 191). If we missed your point here, please let us know.</p><disp-quote content-type="editor-comment"><p>3. The authors show a series of sophisticated experiments to demonstrate the impact of the three drugs. The following clarifications will help strengthen the importance of the evolutionary pipeline to identify these drugs:</p><p>a. Are any of the previously known MECP2 functional partners targeted by EPO, DMF and Pacritinib in DGIdb and Open Targets? For example, a quick literature survey shows that all three molecules have direct or indirect effects on HDAC activity, which are functional and biophysical interaction partners of MECP2.</p></disp-quote><p>We addressed HDACs as well as other known associations with MECP2 , by performing an analysis of the top linked MECP2 genes from the STRING database. Neither HDACs nor other highly-ranked MECP2 associated genes were linked to either EPO or DMF. We used STRING as our baseline method for finding known interactions, since it includes text-mining, co-expression, and experimental associations (which includes links between MECP2 and many HDACs). Additionally, we searched for direct HDAC interactions for all class 1 and 2 HDACs in DGIDB, GeneCards and OpenTargets, and found no links to the 3 drugs we identified here. Below is a list of 46 drugs with direct HDAC association we found through this process.</p><table-wrap id="resptable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Drug</th><th>Interaction</th><th>Gene</th><th>Drug</th><th>Interaction</th></tr></thead><tbody><tr><td>HDAC1</td><td>TACEDINALINE</td><td>inhibitor</td><td>HDAC <break/>1</td><td>VORINOSTA <break/>T</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>PANOBINOSTAT LACTATE</td><td>inhibitor</td><td>HDAC4</td><td>TASQUINIMOD</td><td>allosteric modulator</td></tr><tr><td>HDAC1</td><td>ROMIDEPSIN</td><td>antagonist|inhibitor</td><td>HDAC6</td><td>BUFEXAMAC</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>FIMEPINOSTAT</td><td>inhibitor</td><td>HDAC6</td><td>TUBACIN</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>CUDC-101</td><td>inhibitor</td><td>HDAC1</td><td>Valproic acid</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>SCRIPTAID</td><td>inhibitor</td><td>HDAC1</td><td>Fingolimod</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>RESMINOSTAT</td><td>inhibitor</td><td>HDAC1</td><td>4SC-202</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>NANATINOSTAT</td><td>inhibitor</td><td>HDAC1</td><td>sodium phenylbutyrate</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>APICIDIN</td><td>inhibitor</td><td>HDAC1</td><td>CHR-3996</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>ABEXINOSTAT</td><td>inhibitor</td><td>HDAC1</td><td>MGCD-0103</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>BELINOSTAT</td><td>inhibitor</td><td>HDAC1</td><td>PCI-24781</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>DEPAKOTE</td><td>inhibitor</td><td>HDAC1</td><td>Pivanex</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>MOCETINOSTAT</td><td>inhibitor</td><td>HDAC1</td><td>SB939</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>DACINOSTAT</td><td>inhibitor</td><td>HDAC2</td><td>Theophylline</td><td>activator</td></tr><tr><td>HDAC1</td><td>PANOBINOSTAT</td><td>inhibitor</td><td>HDAC2</td><td>Aminophylline</td><td>activator</td></tr><tr><td>HDAC1</td><td>AN-9</td><td>inhibitor</td><td>HDAC2</td><td>Atorvastatin</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>TUCIDINOSTAT</td><td>inhibitor</td><td>HDAC2</td><td>Fluvastatin</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>RICOLINOSTAT</td><td>inhibitor</td><td>HDAC2</td><td>Oxtriphylline</td><td>activator</td></tr><tr><td>HDAC1</td><td>ENTINOSTAT</td><td>inhibitor</td><td>HDAC2</td><td>Pravastatin</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>GIVINOSTAT</td><td>inhibitor</td><td>HDAC2</td><td>Simvastatin</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>CITARINOSTAT</td><td>inhibitor</td><td>HDAC3</td><td>Romidepsin</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>QUISINOSTAT</td><td>inhibitor</td><td>HDAC3</td><td>RG2833</td><td>inhibitor</td></tr><tr><td>HDAC1</td><td>PRACINOSTAT</td><td>inhibitor</td><td>HDAC7</td><td>TACEDINALINE</td><td>inhibitor</td></tr></tbody></table></table-wrap><disp-quote content-type="editor-comment"><p>b. If the authors were to use known functional partners of MECP2 from Stringdb, PDB, or biogrid and check for their druggability in DGIdb and Open Targets, will the authors identify EPO, DMF and Pacritinib? If not, it proves that the comparative genomic pipeline was critical for identification of these drugs. If yes, it shows that the authors didn't need the pipeline. Or perhaps the authors mean to demonstrate that EPOR, KEAP1 and IRAK work upstream of HDACs and are therefore contributing to a better understanding of the mechanism of action of MECP2. If so, the authors do not have enough text, analysis or experiments to demonstrate that.</p></disp-quote><p>For STRING, please see our response to question 3a above. Biogrid only contains only 182 proteins linked to MECP2, and none are linked to the 3 drugs tested here through these databases. This reinforces what we have shown previously, that PP is complementary to other functional relationship databases. We were not sure what you had in mind for PDB. Only one protein (TBLR1) has a PDB structure in complex with MECP2, and this gene is not linked to any of our 3 drugs. There are three structures with DMF in complex with a human gene (SMN1, UHRF1, TDRD3), two with Pacritinib (NQO2, SMYD3), and none with EPO. Only UHRF1 has any connection to MECP2 through STRING.</p><disp-quote content-type="editor-comment"><p>c. Can the authors perform silencing or knockdown experiment to demonstrate that the effects of the three drugs are mediated through EPOR, KEAP1 and IRAK and not through other targets?</p></disp-quote><p>This is a completely valid point and definitely an important area for future work, as evidenced by the point you brought up about HDACs. We have now added text to our Discussion regarding this on lines 478-483. Given our resources, these experiments would be beyond the scope of what we could accomplish in a short time frame. We believe that our results here, while not 100% conclusive, are highly compelling given the fact that all three drugs predicted by our pipeline showed reversal of multiple Rett-like phenotypes of MECP2 depletion. It seems highly unlikely that by chance we picked three drugs that could reverse these changes in the MECP2 depleted condition but have no effect on the wildtype cells. We believe it is important to publish our initial findings based on this methodological workflow, as well as our gene and drug lists, so that other labs may follow up on these results in parallel to us.</p><p>References:</p><p>Bateman, A. (2019). UniProt: A worldwide hub of protein knowledge. Nucleic Acids Research, 47(D1), D506–D515. https://doi.org/10.1093/nar/gky1049</p><p>Bloch, I., Sherill-Rofe, D., Stupp, D., Unterman, I., Beer, H., Sharon, E., and Tabach, Y. (2020). Optimization of co-evolution analysis through phylogenetic profiling reveals pathway-specific signals. Bioinformatics, 36(14), 4116–4125. https://doi.org/10.1093/bioinformatics/btaa281</p><p>Dunwell, T. L., Paps, J., and Holland, P. W. H. (2017). Novel and divergent genes in the evolution of placental mammals. Proceedings of the Royal Society B: Biological Sciences, 284(1864). https://doi.org/10.1098/rspb.2017.1357</p><p>Fuchs, S. B. A., Lieder, I., Stelzer, G., Mazor, Y., Buzhor, E., Kaplan, S., … Shtrichman, R. (2016). GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data. OMICS A Journal of Integrative Biology, 20(3), 139–151. https://doi.org/10.1089/omi.2015.0168</p><p>Philippon, H., Souvane, A., Brochier-Armanet, C., and Perrière, G. (2017). IsoSel: Protein isoform selector for phylogenetic reconstructions. PLoS ONE, 12(3).</p><p>https://doi.org/10.1371/journal.pone.0174250</p><p>Tsaban, T., Stupp, D., Sherill-Rofe, D., Bloch, I., Sharon, E., Schueler-Furman, O., … Tabach, Y. (2021).</p><p>CladeOScope: functional interactions through the prism of clade-wise co-evolution. NAR Genomics and Bioinformatics, 3(2). https://doi.org/10.1093/nargab/lqab024</p><p>Villanueva-Cañas, J. L., Laurie, S., and Albà, M. M. (2013). Improving genome-wide scans of positive selection by using protein isoforms of similar length. Genome Biology and Evolution, 5(2), 457– 467. https://doi.org/10.1093/gbe/evt017</p></body></sub-article></article>